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Abstract 
Cardiovascular Disease is a growing public health issue in the modern world, 
with a high incidence rate that continues to increase, and poor mortality rates. 
Recent technological advances have made it possible to efficiently derive cardiac 
myocytes from human induced pluripotent stem cells (hiPSC-CMs). These have 
been seen as a model for human heart disease, as well as a potential source for 
cellular transplantation into failing diseased heart tissue. Many laboratories have 
devoted substantial effort to examining the functional properties of hiPSC-CMs, 
including electrophysiology, intracellular calcium handling, and gene/protein 
expression and force. In the first part of this thesis, we utilize traction force 
microscopy (TFM) to determine the maximum force production of isolated hiPSC-
CMs under varied culture and assay conditions. We elucidate here the 
relationship between cell morphology and force production, and find a significant 
relationship between cell size and force. HiPSC-CMs developing in culture for 
two weeks produce significantly less force than cells cultured from one to three 
months and hiPSC-CMs cultured for three months resemble the cell morphology 
of neonatal rat ventricular myocytes. Unexpectedly, hiPSC-CMs produce less 
force when assayed on increasingly stiff substrates, and generate less strain 
energy. Finally, hiPSC-CMs cultured in conditions of physiologic calcium 
concentrations are larger and produce more force than cells cultured in standard 
media. In the second part of this thesis, we address the concept of immaturity in 
hiPSC-CMs, and attempt to accelerate maturation. We use genome editing to 
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engineer hiPSC-CMs that contain an inducible gene expression cassette, in 
order to overexpress two proteins associated with maturity: SERCA2a and 
cardiac troponin I (cTnI). We find that we are able to overexpress both proteins in 
differentiated hiPSC-CMs after two weeks of treatment with doxycycline. 
SERCA2a-overexpressing cells showed significant alterations in physiologic 
function, including increased chronotropy and decreased time to peak in calcium 
transients following treatment with isoproterenol, a β-adrenergic agonist. 
Furthermore, using an impedance-measuring system to track contractility 
kinetics, we found that SERCA2a-overexpressing cells had shortened time to 
peak and time to baseline after gene induction, with continued response to 
isoproterenol. As a sign of maturation, SERCA cells also expressed increased 
cTnI, a key marker of maturity. Using RNAseq, we found that cTnI-
overexpressing cells had marked, global changes in their gene expression 
profile. Key findings include upregulation of genes associated with cardiac 
contractility and development, such as cardiac myomesin and tropomyosin and 
ryanodine receptor, and downregulation of genes associated with pacemaker 
and ventricular cell types, such as HCN and GREM2, and genes associated with 
skeletal myocytes, such as skeletal muscle actin. Overall, our findings show that 
hiPSC-CMs have physiologic function similar to that of immature cardiac 
myocytes, but that we are able to induce maturation by overexpression of genes 
associated with maturity. 
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Chapter 1 
Introduction 
Cardiovascular disease is a critical healthcare problem in the modern 
world, with a high incidence rate and poor mortality rates that have been 
improved by recent technological advances but have yet to fully address issues 
of death and, importantly, quality of life. Human pluripotent stem cells and stem 
cell-derived cardiac myocytes, recently discovered, show great promise in 
decreasing morbidity, mortality, inferior quality of life, and the economic burden of 
such a widespread chronic disease. This thesis focuses on elucidating the 
physiologic function of stem cell-derived cardiac myocytes, particularly in terms 
of force production; on elucidating the maturation status of stem cell-derived 
cardiac myocytes, in terms of physiologic function and protein expression; and on 
the use of genome editing to induce expression of physiologically significant 
genes in order to accelerate maturation and improve function.  
To aid the reader in understanding and drawing conclusions from the data 
presented, and to aid in the understanding of how the ideas presented relate to 
another, this introduction reviews the topics of cardiovascular disease and 
current therapies, cardiac myocyte function and development, stem cells and 
stem cell-derived cardiac myocytes and current experimental uses of those cells, 
and genome editing as a tool for precise genetic manipulation. The current state 
of the field is explored, with reference to both a historical understanding of 
cardiac biology and a history of techniques and experiments that have led to our 
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current understanding, as well as the most recent, cutting-edge, in-progress 
results and models and future directions. 
 
Clinical Relevance 
Epidemiology of Heart Failure 
Looming over the healthcare systems of the world, cardiovascular disease 
has been and continues to be a growing threat to public health and individuals’ 
physical, mental, and social well-being1. While “cardiovascular” is a broad 
umbrella term that includes all major disease states relating to blood flow or lack 
thereof, here I will refer predominantly to another broad category of disease 
centered around the heart itself, which is heart failure. In terms of the history of 
medicine, heart failure has been used to mean any disease where the 
myocardium is unable to adequately produce force to result in adequate cardiac 
output.  
This includes diseases that appear in childhood or adolescence, or the 
congenital cardiomyopathies; diseases that appear at various points throughout 
life, such as viral or post-partum cardiomyopathies; and diseases that occur in 
middle to old age, often referred to broadly by clinicians as congestive heart 
failure (CHF). In both the developed and the developing world, low levels of 
infectious disease and violence have resulted in an aging population with aging 
organs and aging cells, as well as prolonged exposure to environmental factors 
  3 
that contribute to vascular disease, coronary artery disease, kidney disease, and 
obesity.  
Globally, there are currently more than 23 million adults living with heart 
failure, with 6 million in the United States alone2. Worldwide, the prevalence of 
heart failure continues to increase3, although incidence seems to have 
plateaued, and may be decreasing among certain populations1, which may be 
due to decreased incidence among younger individuals alongside increased 
incidence among older individuals4. Mortality following a diagnosis of heart failure 
is high, with estimates of 30-day mortality of 10%, 1 year mortality of 20-30%, 
and 5-year mortality of 45-60%5, and 75% 5-year mortality after the first 
hospitalization6.  
Risk factors for heart failure differ depending on subtype and clinical 
presentation- for example, CHF patients with preserved ejection fraction (HFpEF) 
are more likely to be female and have a history of hypertension7. However, 
several factors are strongly associated with adult heart failure in general, 
including ischemic heart disease, hypertension, diabetes, smoking, and obesity4. 
These often present as comorbidities in the same patient due to lifestyle or 
choices, sharing underlying common pathologies. Chronic kidney disease (CKD) 
shares many of these risk factors and frequently co-exists with CHF8. The 
combination of several chronic diseases such as these can complicate treatment 
algorithms and therapeutic regimens, sometimes confounding diagnostic and 
prognostic analysis.  
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Clinical Presentations of Heart Failure 
Clinical definitions of heart failure have varied wildly over the decades, 
and even today different definitions are put forward by distinct academic 
organizations, such as the American Heart Association, the New York Heart 
Association, and the European Society of Cardiology9. However, most definitions 
include a combination of abnormal findings of left ventricular mass index, ejection 
fraction, left atrium systolic dimension, lower extremity mobility disability, 
summary physical performance score, and 6-minute walk test10. CHF is a 
generally insidious disease, with myocardial damage accumulating slowly over 
years, except in the case of damage due to myocardial infarction. Patient present 
to clinic with dyspnea, orthopnea, paroxysmal nocturnal dyspnea, fatigue, 
edema, and limitations in physical activity, which becomes worse as the disease 
progresses. Any combination of the above symptoms is possible. The New York 
Heart Association (NYHA) classifies symptoms on a functional scale of I, 
meaning no limitation of physical activity, to IV, meaning unable to carry on any 
physical activity without discomfort11. The assessing physician examines the 
patient using physical exam, exercise testing, and imaging to classify the patient 
on the NYHA objective scale of A, meaning no evidence of cardiac disease, to D, 
meaning objective evidence of severe cardiac disease11. 
Diagnosis of heart failure is made based on symptoms and evidence of 
myocardial dysfunction. Echocardiography gives information about diastolic and 
systolic dysfunction, which can be supported by information from cardiac 
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magnetic resonance imaging, vascular imaging, and computed tomography 
imaging to distinguish variations of heart failure from each other and determine 
underlying causes, such as valve disease or vascular disease, and provide 
prognostic information as well12. Blood tests, such as N-terminal pro-brain 
natriuretic peptide (NT-proBNP), which is elevated in heart failure, can provide 
additional information.  
An important piece of the diagnosis to be made is whether ejection 
fraction (EF) is reduced (HFrEF) or preserved (HFpEF). This distinction has 
recently gained traction, as it was previously overlooked or unknown, although it 
is now known that the two versions should be treated slightly differently12. The 
distinction is made based on echocardiographic data; HFrEF is dominated by 
systolic dysfunction, while HFpEF is dominated by diastolic dysfunction, although 
significant overlap exists and may be present in an individual patient13. Heart 
failure can also be classified as high output, having a resting cardiac index of > 
2.5-4.0 L/min/m2 and low systemic resistance, or low output, having a resting 
cardiac index of < 2.5 L/min/m2 14.  
 
Pathophysiology of Heart Failure 
The pathophysiology of heart failure as a clinical syndrome is complex and 
incompletely understood. There are many precipitating events that may lead to 
heart failure, some of which are less common than others, including amyloidosis, 
radiation, constrictive pericarditis, and rare genetic disorders15; genetically-
  6 
encoded cardiomyopathies, including hypertrophic16; pregnancy17; and stress18. 
However, most adult heart failure is precipitated by more common, long-standing 
disease states such as valve disease, hypertension, obesity, renal disease, and 
myocardial infarction following coronary artery disease14. Compensated heart 
failure can progress to acute decompensated heart failure due to ischemia or 
infarction, non-adherence to therapy, uncontrolled hypertension, arrhythmia, 
pregnancy, alcohol intoxication, thyroid conditions, COPD exacerbation, or other 
causes14. 
Underlying most forms of heart failure are pathological processes common 
to many disease states. Inflammation has been implicated as a serious player, 
including upregulation of pro-inflammatory cytokines, such as TNF-α and IL-6, 
and downregulation of anti-inflammatory cytokines; infiltration of inflammatory 
cells into the myocardium, especially macrophages, is seen, and has profound 
effects on myocardial function14. Fibrosis is present in the myocardium, as well 
as in the lungs, is likely due to hypoxia, fibroblast dysregulation, and 
inflammation, and contributes to both systolic and diastolic dysfunction13.  
Metabolic dysfunction is being recognized as an important player in the 
pathogenesis of heart failure and involves insulin resistance, defects in substrate 
utilization, and defects in energy production19. On an organismal level, we see 
enhanced neurohumoral signaling and activity, as well as volume overload in the 
pulmonary and systemic vasculature due to inability of the heart to pump. On an 
organ level, we see ventricle wall hypertrophy, alterations in calcium handling, 
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arrhythmia, and often dilatation of the ventricle and atrium20. We also see 
angiogenesis, fibrosis, autophagy, and apoptosis.  
 
Cell Intrinsic Dysfunction in Heart Failure 
On a cellular level, vast changes occur, such as the switch to fetal gene 
expression, involving troponin isoform switching, myosin heavy chain isoform 
switching, downregulation of Akt signaling and upregulation of ERK signaling, 
increased PKC signaling, increased CaMKII signaling, downregulation of β-
adrenergic signaling, and decreased SERCA2a and dysfunctional calcium 
handling20. Enhanced TGFβ signaling leading to SMAD2/3 activity affects many 
aspects of cardiac myocyte function including hypertrophy, metabolism, and 
contractility21. Stimulation of α1-adrenergic receptors plays a role in hypertrophy, 
but is also preventive against cell death in ischemia-reperfusion22.  
Additionally, autophagy, responding to increased levels of reactive oxygen 
species (ROS), as well as increased AMPK and mToR signaling, increases at 
first as a protective mechanism, but later decreases, seemingly unable to keep 
up with its task, contributing to accumulation of potentially toxic organelles and 
proteins23. Copious amounts of ROS, accumulating in the myocyte due to 
dysfunctional metabolism and energetics, contribute to hypertrophy and 
increased resting tension, and affecting mitochondrial energetics23. Dysfunctional 
calcium signaling over-activates CaMKII, which is protective during stunning, but 
harmful during ischemia-reperfusion24. The Hippo pathway can be activated by 
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ROS, GPCR signaling, and mechanical stress, all of which are present in failing 
myocardium, and can lead to hypertrophy and apoptosis, and downregulation of 
the pathway can improve cardiac regeneration25.  
 
Treatment of Heart Failure 
Treatment of heart failure is mostly symptomatic, relying on medications 
that decrease extracellular fluid volume and decrease mechanical load on the 
heart through decreased fluid volume, decreased peripheral vascular resistance, 
and decreased cardiac chronotropy and inotropy. These are frequently used 
alongside medications that treat comorbidities, such as nitric oxide donors for 
patients suffering CAD, statins for patients with high cholesterol, diuretics for 
patients with hypertension, anti-clotting agents for patients with atrial fibrillation, 
and diabetes medications26; patients on many medications simultaneously 
means there is high probability of medication interactions. First line medications 
are ACE inhibitors or angiotensin receptor blockers, which decrease 
vasoconstriction, hypertension, and cardiac and pulmonary fibrosis, although 
data from clinical trials of both drugs in HFpEF patients is not entirely 
conclusive26. Beta blockers, which block activation of β-adrenergic signaling, are 
recommended for patients with a history of myocardial infarction, hypertension, 
or atrial fibrillation14. Other classes of drugs are available, and many others, such 
as those targeting dysregulated pathways mentioned above, are in clinical trials 
or are elsewhere in the research and development pipeline.  
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Mechanical devices, known as left-ventricular assist devices (LVADs), 
have gained importance as an end-stage treatment option; outcomes can be as 
good as patients who have undergone heart transplant, providing between 2-5 
quality-adjusted life years (QALYs), although LVADs bring with them several 
major problems, including high rates of infection and prohibitive cost of device, 
implant procedure, and subsequent management27. Heart transplantation remain 
the final treatment in severe congenital cardiomyopathies, and is an option in 
other forms of end-stage heart failure in patients who are able to match with a 
donor. Heart transplant can add several QALYs to a patient’s life, but also have 
several serious, persistent issues, such as infection and allograft vasculopathy28. 
 
Uses of Stem Cells as a Therapy in Heart Failure 
More recently, a large effort has been made in both academic and 
industrial research laboratories to explore cardiac regeneration, as a more 
permanent therapy that targets the underlying pathophysiology of cardiac 
myocyte dysfunction by providing new, young cardiac myocytes to repopulate the 
myocardium and provide both systolic and systolic support. This can be done by 
either inducing native cell populations to divide and differentiate, or by utilizing 
cell therapy to transplant new cells, including stem cells and stem cell-derived 
cardiac myocytes or cardiac myocyte progenitors29-30.  
A landmark study utilizing carbon-14 dating showed some amount of 
cardiac turnover in the adult heart31. Several endogenous populations of cells in 
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the adult heart have been hypothesized to be cardiac progenitors capable of 
regenerating mature cardiac myocytes, including side population cells, c-kit+ 
cells, and other mesenchymal cell types, with potential therapies aimed at 
stimulating increased proliferation and differentiation of these cells. However, 
basic science data demonstrating clear proliferation and regeneration in native 
tissue of any of these cell types is severely lacking32. Other work has focused on 
reprogramming native non-progenitor cell populations into cardiac progenitors by 
overexpressing reprogramming factors, such as transcription factors associated 
with pluripotency33. 
As an alternative to native cell populations, stem cells could be 
transplanted into the myocardium, with the hope that they would either engraft, 
and then differentiate or mature (depending on cell type) and substantially 
contribute to mechanical function and strength of the organ, or provide paracrine 
signals that promote myocyte regeneration, ECM remodeling, and anti-
inflammatory chemicals. Several cell types have been proposed as suitable for 
cell transplant; a major divide lies along whether the cells are pluripotent, such as 
cord blood cells, bone marrow stem cells (BMSCs), mesenchymal stem cells 
(MSCs), embryonic stem cells (ESCs), or induced pluripotent stem cells (iPSCs), 
or whether they are cardiac progenitor cells (CPCs) or cardiac myocytes (CMs) 
that have been differentiated from one of the above cell types30.  
 
Stem Cell Biology 
  11 
Definitions 
Stem cells are cells that differentiate into one or more terminal cell types, 
and self-renew during the mitotic process, distinguishing them from progenitor 
cells, which are also able to differentiate into terminal cell types but do not self-
renew34. Progenitor cells are derived from stem cells or from other progenitor 
cells. Stem cells are abundant throughout embryonic and fetal development, and 
specialized niches containing stem cells exist in the adult. Adult niches 
containing numerous stem cells include bone marrow, hair follicles, epidermis, 
intestinal crypts, gonads, liver, adipose tissue, and vasculature; these tend to be 
organs with high rates of cellular turnover and regeneration. Niches with few 
stem cells as a percentage of total organ cell number include skeletal muscle, 
brain, and bone and cartilage, where turnover rates are low and cell replacement 
is infrequent35. The existence of stem cells in the heart is a highly-contested 
topic36.  
The number of different cell types a stem cell has the capacity to 
differentiate into defines its potency. A stem cell that can be differentiated into 
one cell type is unipotent, although there is argument over whether unipotent 
stem cells exist, or whether they are, in fact, progenitor cells; an example is a 
hepatoblast. A stem cell that can differentiate into a few cell types is oligopotent, 
such as vascular stem cells. Those that can differentiate into more cell types than 
an oligopotent cell, but not all cell types, is multipotent, such as cord blood stem 
cells, BMSCs, and MSCs. A cell that can differentiate into all cell types derived 
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from any of the three embryonic germ layers is pluripotent; these include ESCs, 
iPSCs, and embryonic cells including inner cell mass (ICM) cells and epiblast 
cells. Finally, a totipotent cell can differentiate into cell type of any of the three 
germ layers, as well as cells derived from placental cytotrophoblast and 
syncytiotrophoblast. The only cells capable of this in the human are the zygote, 
cells in the morula, and cells existing in mitotic stages between zygote and 
morula37.  
Embryonic stem cells are derived from the inner cell mass of blastocysts, 
typically from blastocysts created during in vitro fertilization procedures that are 
not chosen to implant into the mother’s uterus30. They are pluripotent, capable of 
differentiating into all three embryonic germ layers, and have been successfully 
differentiated into immature cardiac myocytes. These ESC-derived cardiac 
myocytes (ESC-CMs) are characteristically immature, especially in terms of their 
ultrastructure, electrophysiological properties, and sarcoplasmic reticulum38. This 
immature phenotype presents problems for using ESC-CMs as models of human 
cardiac myocytes for studying disease, as well as potential problems for use of 
them as transplantable cell therapies, although this is not any different than 
hiPSC-CMs, which suffer from similar, if not the same, problems.  
Furthermore, ESCs bring with them two major problems when being 
considered for therapeutic use: first, a substantial proportion of the general 
public, especially in the United States, as well as some scientists, have ethical 
issues with the destruction of blastocysts for science. Second, because ESCs 
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and cells derived from them are genetically non-identical to the host that they are 
transplanted into, there is an elevated risk of a host immune response to 
transplanted cells, which has already been shown in some models39. Despite 
this, several studies have shown benefits of transplantation of ESC-CMs into 
animals with infarcted hearts, with improvements in EF, wall thickness, and 
adrenergic response38.  
Because of the challenges of ESCs, both real and perceived, and because 
of the benefits of hiPSCs, both real and perceived, the field of cardiac 
regeneration and cardiac differentiated has moved resolutely towards hiPSC-
CMs as the cell of choice. Work on reprogramming somatic cells into pluripotent 
cells began in in the 1960’s and 1970’s, when John Gurdon transferred the 
nucleus of a frog somatic cell into an enucleated egg, allowing the animal to be 
cloned40, opening an era of vertebrate cloning that has had far-reaching effects 
even until today, such as in agriculture, where somatic cell nuclear transfer 
(SCNT) is routinely performed.  
iPSCs were discovered, or rather created, by a group led by Shinya 
Yamanaka in 2006, ten years ago41. They accomplished this by overexpressing 
four crucial genes associated with a pluripotent state- Oct4, Sox2, Klf4, and c-
Myc, although it was later shown that c-Myc was not required for reprogramming, 
and slightly inhibits differentiation into hiPSC-CMs42. Initially this overexpression 
was driven by viral vectors, which can integrate and persist in the cells, 
potentially leading to immunogenicity, and potentially disrupting differentiation to 
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other cell types. Viral induction of pluripotency may also lead to oncogenicity due 
to activation of oncogenes, as well as functional mutations caused by viral 
vectors inserting into the genome43.  
Alternatively, pluripotency can be induced through non-integrating 
methods, including chemicals that mimic transcription factors44, adenovirus45, 
plasmid46, or recombinant proteins47. iPSCs have been found to be very similar 
to ESCs in terms of their chromatin structure and methylation patterns, 
morphology, cell surface markers, and differentiation capacity48.  
 
Differentiation of Pluripotent Stem Cells 
Since the discoveries of ESCs and iPSCs, efforts have been made to 
differentiate these pluripotent cells into progenitor cells or terminally differentiated 
cell types; so far, researchers have been productive in differentiating 
hepatocytes, endothelial cells, fibroblasts, neuronal cells, pancreatic cells, 
hematopoietic cells, vascular cells, and retinal pigment epithelial cells49. Each cell 
type comes about through different developmental conditions, in response to 
various environmental cues including growth factors, cytokines, chemokines, 
chemical gradients, ionic gradients, electrical signals, haptic signals involving 
different textures, passive stiffness, nutrient availability, and mechanical signals 
including stretch, compression, shear stress, and compartments filling with fluid. 
Thus, differentiation of a desired cell type means that either culture conditions 
must be tailored to that particular cell type, and must closely recapitulate the 
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conditions that the cell experiences in the embryo during development, or that 
cells must be allowed to differentiate into all cell types at once, and desired cell 
types have to be selected for afterwards.  
Early protocols for differentiation of cardiac myocytes from pluripotent 
stem cells took the second approach- adherent cells were dissociated and 
cultured in non-adherent dishes, where they proliferated into clusters of cells 
known as embryoid bodies (EBs), which contain cell types from all three 
embryonic germ layers50. Both epithelial and mesenchymal cell types appear in 
EBs, and tissue-like structures are also observed; without any additional 
manipulation of culture conditions, EB cell types have a propensity towards 
ectodermal lineages, such as neuronal and dermal cell types, although addition 
of various chemicals and growth factors can coax EBs to form predominantly 
endodermal or mesodermal cell types51. Furthermore, dissociation of EBs and 
replating of isolated cells onto adherent dishes or into methylcellulose, along with 
additional manipulations of culture media, can further direct the cells towards 
specified lineages.  
Early cardiac myocyte differentiation protocols relied on some percentage 
of embryoid bodies containing spontaneously arising, spontaneously beating 
cardiac myocytes which expressed critical cardiac myocyte progenitor markers, 
such as Nkx2.5, and had crucial ionic currents, although they lack certain 
currents as well52. The protocol has been improved significantly, with additions to 
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the media, such as Wnt inhibitors and nitric oxide, enhancing the percentage of 
cells that express cardiac markers53-54. 
Alternatively, embryoid body formation can be bypassed, and pluripotent 
stem cells can be treated with environmental factors that recapitulate the 
embryonic milieu as closely as possible. The goal is to direct the cells towards 
differentiation into the most cardiac myocyte-like cells as possible, while using 
the simplest culture conditions possible; simpler culture conditions have the 
benefits of reproducibility between labs and individuals, leading to standard cells 
that can be experimented on by different groups while still being able to compare 
results between them, as well as reduced cost, allowing more cells to be 
generated for increasing numbers of experiments or transplant. If they are to be 
used for transplant, simpler culture conditions and lower costs mean reduced 
barriers to clinical implementation for greater numbers of individuals. The 
simplest way to do this is by using chemicals that can be added to the medium at 
prescribed time points during the differentiation process; growth factors, or small 
molecules that inhibit growth factors, are easily additive and do not require the 
technical skill of genetic overexpression.  
This, however, is rather complex, as the development of the heart and of 
cardiac myocytes in the embryo relies on enormously complicated networks of 
signaling from various neighboring cell types55. The first step in producing cardiac 
myocytes is differentiation of mesoderm, which happens during gastrulation of 
the epiblast, which in turn is formed from the inner cell mass (ICM). This is 
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important because human embryonic stem cells and induced pluripotent stem 
cells resemble epiblasts in terms of gene expression patterns56, although mouse 
embryonic stem cells resemble ICM cells, and mouse epiblast cell lines can be 
derived57. Furthermore, human pluripotent stem cells can be pushed towards the 
naïve ground-state of ICM pluripotent cells through culture conditions which are 
distinct from those required for maintaining the ground state of murine ground-
state cells; ground-state pluripotent cells may differentiate more efficiently to 
cardiac myocytes than cells that retain the epiblast-like signature58. The 
conversion between the two appears to depend on the presence (in ground-
state) or absence (in epiblast-like cells) of Wnt signaling59.  
 
Cardiac Development 
Induction of mesoderm at the primitive streak during gastrulation depends 
on many factors including Nodal, bone morphogenic protein (BMP), Wnt, and 
fibroblast growth factor (FGF)60. Thus, differentiation protocols that intend to 
produce mesodermal lineages must start with a step that activates this induction. 
Thus, early protocols to differentiate ESC-CMs or iPSC-CMS began with addition 
of BMP4, bFGF, and Activin A to culture61-63. Variations on this protocol included 
one or two of the three, aforementioned growth factors, or combinations of these 
added at various times over the course of the first one to four days, enough time 
for mesoderm to fully develop.  
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Next, the mesoderm must differentiate to a cardiac myocyte; in the 
embryo, it does this through several steps and cell types- first, cardiogenic 
mesoderm progenitors develop, which express MesP155. These cells migrate to 
an anterior lateral position caudal to the head folds and form the cardiac 
crescent, which contain the first and second heart fields (FHF and SHF). The first 
heart field will contribute to the heart tube and will eventually give rise to cardiac 
myocytes and smooth muscle cells; FHF cells express Nkx2.5 and Tbx5. Second 
heart field cells will also contribute to the heart tube, and will give rise to cardiac 
myocytes, smooth muscle cells, and endothelial cells; they express Nkx2.5 and 
Isl1. The second heart field will also give rise to proepicardium, which will 
develop into the epicardium and some cardiac muscle tissue. Increased levels of 
BMP and FGF contribute to both the first and second heart fields; however, the 
first heart field is associated with decreased canonical Wnt, and the second heart 
field is associated with increased canonical Wnt signaling.  
Development of both the first and second heart fields is also associated 
with vascular endothelial growth factor (VEGF) and Dickkopf-1 (DKK1)55. So, 
early defined culture conditions for differentiation of cardiac myocytes from 
pluripotent cells by treatment with VEGF, DKK1, and FGF, or some combination 
of the three, in order to push the mesodermal cells towards a cardiac progenitor 
cell type61. From there, the first and second heart fields develop into the heart 
tube, which folds and becomes a primitive organ; further signaling, both chemical 
and otherwise, promotes development of the myocardium. For most 
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differentiation protocols, these signals are too complex and unknown to 
effectively contribute to further myocyte development, and so they rely on the 
passage of time to take the cells from cardiac progenitor to cardiac myocyte61. 
 
Small Molecules and the Matrigel Sandwich Method 
However, because growth factors are peptides or proteins, they are time-
consuming to produce, and expensive. Organic small molecules that mimic the 
effects of growth factors are significantly cheaper, and cheaper reagents mean 
that more differentiated cells can be produced, which is ideal for a lab proposing 
to study many conditions, or many drugs, or for a transplant patient that may 
require hundreds of millions or billions of cells64. Accordingly, several groups 
have developed protocols that utilize small molecules; they differ by the 
pathways activated, the specific drugs used to activate them, and timing of 
addition of small molecules to culture media (after 24 hours vs after 48 hours, 
etc.). The most widely accepted protocol has been the one called either the 
“matrix sandwich method” or “Matrigel sandwich method,” due to the first step of 
dissolving Matrigel (a collection of ECM proteins derived from mouse tumors) into 
the differentiation media on the first day of the protocol; this protocol was 
developed by researchers at the University of Wisconsin, Madison65. 
This protocol begins with iPSCs that are nearly confluent, having been 
passaged approximately 4 days beforehand. Cells are treated with a chemical 
called CHIR99021, which inhibits GSK3, thereby allowing beta-catenin to be 
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released and act as a signaling molecule, effectively activating the canonical Wnt 
pathway. This is given in conjunction with the Matrigel as mentioned above. The 
media used here is RPMI with a supplement called B27, which was originally 
designed for use in differentiation and culture of neuronal cell types, and which 
contains nutrients and is serum-free (Thermo Fisher). For the first several days, 
the media is insulin-free. Three days later, one of several molecules used to 
inhibit Wnt signaling pathways is given. Thus, the protocol uses activation of Wnt 
to differentiate iPSCs into mesoderm, and later inhibition of Wnt to push the cells 
towards a cardiac lineage. After that, cells are allowed to develop in culture until 
they begin to beat spontaneously, at which point they are fed with media 
containing insulin, which has been shown to inhibit differentiation of cardiac 
mesoderm66, but which promotes cardiac growth and hypertrophy later67-68. 
Once the stem cells are differentiated into cells that contract 
spontaneously and morphologically resemble cardiac myocytes, the issue of 
what to use the cells for remains. The two major schools of thought are that they 
could be transplanted into failing hearts, or hearts suffering cardiomyopathy, or 
hearts that have suffered infarction, with the hope that they could engraft and 
contribute mechanically to wall motion and strength64. Those that are 
unenthusiastic about the immediate use of iPSC-CMs as a transplantable 
therapy, as well as some that are, believe that they are better used as a model 
for cardiac myocyte function, or at least for myofibril function69.  
 
  21 
Uses of Stem Cell-Derived Cardiac Myocytes 
Stem Cell-Derived Cardiac Myocytes as Therapy 
Pluripotent stem cells and derived cardiac myocytes have excited 
researchers with the prospect of being used as a clinical therapy. In the field of 
cardiology, there is great interest in using these cells as a potential treatment for 
heart failure and post-infarction cardiomyopathy. Pluripotent stem cell-derived 
cardiac myocytes injected directly into the myocardium are an obvious starting 
point. If these cells can engraft and electrically couple to existing myocardium 
they might provide sufficient contractile force to improve cardiac output. On the 
other hand, the cells may not survive the procedure, or may fail to couple to 
native myocytes, or may even be detrimental, as the procedure may cause 
deadly arrhythmias. These potential complications warrant extensive basic 
research before translation to human studies.  
Several groups have published results from experiments injecting stem 
cells into animal models. It was demonstrated that hESC-CMs transplanted into 
immunocompromised NOD-SCID mice that had undergone myocardial infarction, 
engrafted and transiently improved cardiac function70. Transplanted cells were 
tracked by GFP and anti-human-protein antibodies and the GFP+ cells were 
detected in the heart at least 12 weeks after transplant. The authors proposed 
functional coupling of transplanted and native cells based on connexin-43 and 
desmoplakin staining. Four weeks after transplant, transplanted mice had greater 
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EF than non-transplanted controls; however, this difference in EF was lost 12 
weeks after transplant.  
Two important caveats to these results should be considered: first, the 
population of transplanted cells, taken from beating EBs, was only 20–25% CMs. 
Second, connexin and desmoplakin staining are incomplete evidence of 
functional coupling in the absence of electrical or ionic data, especially since, as 
the authors noted, gap junctions and desmosomes were seen between hESC-
CMs and themselves, but not between hESC-CMs and native myocytes. The 
same group later published results after injecting 3 times as many cells as 
previously, but noting, again, no functional improvement 12 weeks post-
transplant71.  
In a similar study, EB-derived hESC-CMs were transplanted into male 
Sprague–Dawley rats that had undergone LAD and were treated with 
cyclosporine A and methylprednisolone to prevent rejection72. They reported 
evidence of engraftment of cells by imaging GFP or by staining for human 
markers, noting engraftment took place mostly in the border zone of the infarct 
region. Echocardiography showed decreased LV dilatation, greater fractional 
shortening (FS), and decreased pulmonary congestion in animals transplanted 
with hESC-CMs.  
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In an effort to improve engraftment, human ES-CMs were transplanted 
into infarcted rat hearts along with a “pro-survival cocktail (PSC)” that included 
Matrigel, a peptide from Bcl-XL, cyclosporine A, pinacidil, IGF-1, and a caspase 
inhibitor ZVAD-fmk63. This group detected engraftment based on human specific 
immunostaining and qPCR. Based on echocardiography, hearts transplanted 
with hESC-CMs showed decreased left ventricular end systolic diameter 
(LVESD) and increased FS, as well as increased thickening of the left ventricular 
wall in the infarct region.  
Later, they published a similar study73, this time injecting cells 1 month 
after infarction. This treatment improved cardiac function, but did not alter 
dimensions or geometry of the myocardium. In 2012, this group published a 
study74 using transplanted cells in immunosuppressed guinea pigs, wherein they 
sought to demonstrate electrical coupling between hESC-CMs and host 
myocytes using the genetically encoded calcium sensor GCaMP3. To do this, 
they correlated fluorescent transients to ECG to determine synchrony. They also 
showed fewer arrhythmias in the form of premature ventricular contractions 
(PVCs) and ventricular tachycardia (VT) in transplanted animals versus controls. 
However, in their isolated heart studies, they demonstrated heterogeneous 
calcium transients and incomplete coupling, as well as a loss of coupling at 
higher pacing frequencies.  
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In a technical tour de force, this group transplanted hESC-CMs into a non-
human primate model of infarction64. The hESC-CM transplanted animals 
responded differently to treatment; while some had improved EF after transplant, 
some had no improvement. Perhaps most concerning, all hESC-CM transplanted 
animals displayed increased arrhythmias following transplant. This important 
study represents the current state of stem cell engraftment. It will be important to 
see follow-up studies in coming years as the issues of stable, physiological 
engraftment and functional restitution are established.  
 
Stem Cell-Derived Cardiac Myocytes as a Model of Human Disease 
Pluripotent stem cells derived from individuals with genetic diseases can 
be used to illuminate disease phenotypes in an in vitro model. Here, iPSC-CMs 
derived from patients with known genetic mutations, especially monogenic 
mutations, that lead to cardiac phenotypes can be used to probe gene function 
and potential therapies. With the electrical assays readily available as mentioned 
above, an early target for disease modeling with iPSC-CMs was Long QT 
syndrome, a genetic disorder characterized by delayed repolarization of cardiac 
myocytes, a disease that places patients at risk of deadly arrhythmias including 
Torsade de Pointes and ventricular fibrillation75. In hiPSC-CMs from patients with 
Long QT Syndrome Type 3 (LQTS-3) (caused by mutations in the sodium 
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channel SCN5A) there is faster recovery from inactivation of Na+ current in 
mutant cells versus wild-type cells, and a larger tetrodotoxin (TTX)-sensitive 
current in the mutant cells75. Both of these findings are consistent with data from 
adult mouse myocyte studies76. The group also found prolonged AP duration in 
SCN5A mutant cells.  
Similar observations were made using iPSC-CMs from LQTS-3 patients, 
however with different mutations in the SCN5A gene77. Using patch clamp to 
study Na+ and Ca2+ currents, as well as whole-cell current clamp to measure AP, 
they found that LQTS cells have tendencies toward prolonged AP duration, 
smaller Na+ current density, slower time to inactivation, and increased time to 
peak.  
At least three groups have studied LQTS using pluripotent cells from 
patients with LQTS Type 2, caused by mutations in KCNH2 (hERG channel, 
responsible for inwardly rectifying potassium current IKr). One group, using cells 
from a single patient, utilized whole-cell patch clamp and found AP duration 
prolongation and reduced amplitude of peak IKr activation and tail currents78. 
Using MEA, they reported prolonged field potential duration (FPD). Importantly, 
by looking at single cell AP as well as MEA, they found significant 
arrhythmogenicity in the form of EADs and ectopic activity. The second79 and 
third groups80 found similar prolongation of APD and FPD in KCNH2 mutant 
iPSC-CMs. Furthermore, these studies demonstrated significant reduction in IKr 
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density and enhanced arrhythmogenic potential. In hiPSC-CMs from a patient 
with Timothy syndrome [caused by a mutation in the L-type Ca2+ channel 
(CaV1.2)] the QT interval was prolonged81. This study reported prolonged APD, 
arrhythmic activity, and abnormal Ca2+ transients in the patient-derived cells 
compared to control cells. 
Other models of arrhythmia have been studied using patient-derived cells. 
Catecholaminergic polymorphic ventricular tachycardia (CPVT), caused by a 
mutation in the ryanodine receptor (RYR2), is characterized by aberrant Ca2+ 
release from the SR and ventricular arrhythmia. Cells derived from patients with 
this disease indeed show elevated diastolic Ca2+ concentrations, reduced SR 
Ca2+ content, and susceptibility to DAD in patient derived cells compared to 
control82. Apart from arrhythmic disease models, other hereditary conditions have 
been studied in patient-derived iPSC-CMs. Using cells derived from a patient 
with Barth Syndrome, a mitochondrial disorder, it was observed that the cells 
closely recapitulated several hallmarks of the disease, including irregular 
sarcomere formation, irregular mitochondria, and weak contractility83. 
Furthermore, they were able to elucidate mechanisms of pathophysiology of the 
disease involving excess reactive oxygen species.  
Others have studied cells from a patient with Pompe disease, a glycogen 
storage disorder caused by mutations in acid alpha-glucosidase (GAA)84. Here 
the patient-derived hiPSC-CMs showed abnormally high levels of glycogen and 
mitochondrial dysfunction, and ultrastructural abnormalities, consistent with 
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findings from myocytes. In LEOPARD syndrome, a developmental disorder 
characterized by a cluster of abnormal findings caused by mutations in the Ras-
MAPK signaling genes, a common abnormality is hypertrophic cardiomyopathy. 
Differentiated iPSC-CMs derived from patients with a mutation in a protein 
tyrosine phosphatase encoded by PTPN11, display abnormal Ras-MAPK 
signaling, cell hypertrophy and abnormal sarcomere organization85. 
Models of cardiomyopathies, while more difficult to study due to the 
immature phenotype of iPSC-CMs, have also shown some progress. For 
example, cells have been taken from a patient with arrhythmogenic right 
ventricular cardiomyopathy (ARVC), a poorly-characterized disease associated 
with arrhythmia and sudden cardiac death, as well as fibrofatty replacement of 
the right ventricular myocardium86. This patient had a mutation in PKP2, 
encoding plakophilin 2, a desmosomal protein. The hiPSC-CMs from this patient 
showed decreased expression of desmosomal proteins and high levels of lipid 
storage.  
A separate in vitro model of dilated cardiomyopathy (DCM)87, 
characterized by eccentric ventricular hypertrophy, decreased Ca2+ sensitivity, 
and impaired force production, was derived from iPSCs from patients carrying a 
mutation in cardiac troponin T (TNNT2) and their unaffected family members. 
Mutant iPSC-CMs showed comparable cell size to control, but had deranged 
sarcomere organization. They also had smaller Ca2+ transient amplitudes and 
smaller SR Ca2+ stores, and lower force production based on an atomic force 
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microscopy assay. Overall, the immaturity of the iPSC-CMs makes more 
challenging the ability to fully assess a disease phenotype normally associated 
with mature myocytes. 
 
Genome Editing to Model Human Cardiovascular Disease 
A recent area of great research interest involves the use of genome 
editing techniques. These include such technologies as transcription activator-
like effector nucleases (TALENs) and CRISPR/Cas9. Both cleave DNA in a site-
specific manner, which may be repaired by non-homologous end-joining (NHEJ), 
potentially disrupting the gene, or, if a template is provided, by homology-directed 
repair (HDR)89. These can be used to introduce disease-specific mutations into 
an otherwise healthy cell line, reducing noise from genetic variability between 
lines. It may also be used to correct disease-causing mutations.  
Hematopoietic diseases such as Fanconi Anemia, β-thalassemia, and 
myelodysplastic syndrome have been modeled and corrected89, but the 
technology has not yet been extensively applied to cardiovascular disease. 
Together, these studies demonstrate the feasibility and wide-reaching capacity 
for modeling genetic diseases using iPSC-CMs. Emerging and advancing 
technologies will allow this capacity to increase even further, and significant 
advances may come from these studies that may not be found in rodent and 
animal models. 
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Stem Cell-Derived Cardiac Myocytes for Drug Discovery 
HiPSC-CMs express ion channels, including sodium channels, potassium 
channels, the hERG (Kv1.1) channel, and the hyperpolarization-activated cyclic 
nucleotide-gated (HCN) channel (funny current), that have the potential to 
interact with many pharmaceutical compounds90. Pharmaceutical researchers 
have a strong interest in identifying interactions between these channels and 
potential clinical drugs due to the severe risks that such interactions entail. As 
such, iPSC-CMs present an attractive alternative for other models, such as 
isolated adult myocytes, or human embryonic kidney cells or Chinese hamster 
ovary cells that have been used to force expression of hERG channels. These 
earlier techniques, where a single channel in a non-myocyte is probed, can miss 
a potential drug interaction. A better approach is to use a cell expressing many 
types of ion channels, in order to more accurately assess all potential 
interactions.  
One group, using MEA, tested the effects of eleven reference compounds 
on electrical activity of iPSC-CMs91. Of these, 5 were hERG blockers, 2 were 
Ca2+ channel blockers, 1 was a nonselective Ca2+ channel/hERG blocker, 1was a 
KATP-channel blocker, and 2were IKs blockers. The hERG blockers all prolonged 
the FPD, as expected, and the Ca2+ blockers shortened the FPD, as expected. 
The IKs blockers had only minor effects on FPD, but there was no expected 
response for either, and the authors were able to use the iPSC-CMs to evaluate 
the potential role of these drugs as well as the role of the IKs current in cardiac 
  30 
myocyte function. Furthermore, as mentioned above, iPSC-CMs can be useful 
models for channelopathies, including Long QT syndrome, where the risk of a 
fatal drug interaction is much higher than in a healthy individual. 
Using cells from a LQTS-2 patient, effects of three compounds including 
nifedipine, a Ca2+ channel blocker; pinacidil, a KATP-channel opener; and 
ranolazine, a Na+ channel blocker were also examined78. All three drugs had 
predictable effects on LQTS iPSC-CMs, namely antiarrhythmic effects, 
demonstrating the ability of these cells to recapitulate the in vivo effects of anti-
arrhythmic drugs in an in vitro system. A second group, used another LQTS-2 
iPSC line, and showed the ability of an IKr blocker, E4031, to prolong APD/FPD, 
and of a KATP-channel opener, nicorandil, to shorten APD and abolish EADs79. 
Furthermore, they demonstrated counteracting effects of isoprenaline, a β-
adrenergic receptor agonist, and nadolol or propranolol, both β-adrenergic 
antagonists. On the other hand, the arrhythmogenic effects of the β antagonist 
sotalol were demonstrated at high concentrations when applied to LQTS iPSC-
CMs, but not control iPSC-CMs80. Moreover, other research groups82 have been 
able to show positive effects of dantrolene on aberrant Ca2+ handling in cells 
from a patient with CPVT.  
Taken together, these studies in healthy as well as diseased cells show 
that iPSC-CMs can robustly examine the effects of current-affecting drugs on 
myocytes, and may be able to predict effects in future studies. Additionally, as 
shown above91, iPSC-CMs can be useful for examining the mechanism of action 
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of untested compounds. In this context, there is a report of altered hypertrophic 
signaling via the α-adrenergic pathway in hiPSC-CMs that should be addressed 
by detailed further study when pursuing iPSC lines for drug discovery92. 
 
Physiologic Function of Stem Cell-Derived Cardiac Myocytes 
In order for researchers to effectively use hiPSC-CMs as either a platform 
for modeling cardiovascular disease, or as a platform for drug discovery and 
testing, it is necessary to examine the physiologic function of the cells. Several 
methods have been used, to examine areas of function such as calcium 
handling, electrophysiology, and contractility.  
 
Electrical Function of Stem Cell-Derived Cardiac Myocytes 
Due to the essential role of ionic currents and electrical conduction in the 
functionality of cardiac muscle, deciphering electrical function of iPSC-CMs 
allows researchers to characterize mature versus immature, healthy versus 
diseased cells, and ventricular versus atrial cell types. However, at such an 
immature state, the last categorization may be difficult to distinguish, and 
attempting to do so may not provide realistically useful information93. Generally, 
electrical function is measured using extracellular field potential recordings, sharp 
electrode recordings, or patch clamp recordings. Perhaps the easiest electrical 
assay to perform is the recording of extracellular field potentials using a 
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multielectrode array (MEA). MEA recording does not require recording from a 
single cell, but rather measures the voltage from a population of cells in a dish94.  
In cardiac myocytes, the field potential duration (FPD) corresponds to the 
action potential duration (APD) of a single cell, which in turn corresponds to the 
QT interval on the electrocardiogram, an important parameter for researchers 
using iPSC-CMs to model arrhythmic diseases or as a platform for drug 
discovery. This technique has been well validated in hESC-CM models94-96. It has 
recently been further validated in iPSC-CMs, demonstrating that it can be used to 
reliably detect drug induced arrhythmias and repolarization delay, even across 
distinct facilities97. Recent work characterized and optimized field potential 
recordings, including in response to a drug, and included some limitations of the 
method that should be taken into consideration when performing experiments 
and data analysis98. 
In order to dissect out the role of specific currents and ions, single cell 
electrophysiology techniques are useful, including patch clamp and sharp 
electrode recording. A patch-clamp pipette can be attached to the cell in several 
configurations, including cell-attached, whole cell, and perforated-patch modes. 
Patch clamp has been used to evaluate currents in hiPSC-CMs derived from 
patients with long QT syndrome type 2. This technique was employed to examine 
the effects of various drugs on those cells, demonstrating its value in studying 
models of arrhythmia79. Patch clamp electrophysiology has also been used to 
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evaluate individual currents of iPSC-CMs, including INa, ICa, IKr, and IKs, as well as 
their ability to be blocked by known channel blockers99. It was concluded that use 
of iPSC-CMs for electrophysiology studies is feasible. Similar experiments using 
an automated patch clamp technology came to similar conclusions100.  
However, a separate group, using patch clamp to study APD, AP 
frequency, AP shape, INa, and ICa, as well as effects of channel blockers TTX and 
lidocaine, noted significant variability between cells from different sources, and 
suggest utilizing these techniques with caution101. Sharp electrode 
electrophysiology has been used in several published iPSC-CM studies. 
Intracellular recordings of APs of murine iPSC-CMs102 and human iPSC-CMs103 
have been made to examine whether the cells differentiated into atrial, 
ventricular, or nodal types. However, due to the immature nature of these cells, 
cell types can be difficult to distinguish based on AP shape alone, and caution 
should be used when drawing conclusions from these types of experiments. 
Overall, these studies show that iPSC-CMs express appropriate ion channels 
and have electrical activity similar to human cardiac myocytes, and can be 
reliably tested for action potential duration, ion currents, and drug interactions if 
appropriate precautions are taken when drawing conclusions. 
Calcium Handling in Stem Cell-Derived Cardiac Myocytes 
The adult ventricular cardiac myocyte displays a well-defined sequence of 
events with regard to Ca2+ cycling. Ca2+ influx via L-type Ca2+ channels serves as 
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an initial trigger, initiating Ca2+ release from the sarcoplasmic reticulum by 
activating Ryanodine receptor 2 (RyR2) via a process called calcium-induced 
calcium release (CICR)104-105. Phosphorylation of these channels increases 
calcium flux, increasing contractility. In general, little is known about the 
excitation contraction coupling (ECC) and Ca2+ handling properties of hiPSC-
CMs. Gene expression and immunostaining studies showed that key Ca2+ 
handling proteins are expressed in hiPSC-CMs106.  
Furthermore, hiPSC-CMs are dependent on both trans-sarcolemmal Ca2+ 
entry via L-type Ca2+ channels and on RYR2-regulated SR Ca2+ release and 
functional SERCA2a pump-based Ca2+ reuptake106. The majority of Ca2+ in the 
cytoplasm during systole is released from and then taken back up into the 
sarcoplasmic reticulum (SR)107. Release is triggered by depolarization of the cell 
membrane, and, as such, is intricately connected to AP activity of the cell as well 
as sarcomere contraction. However, it can be uncoupled from both, and it is 
necessary to measure Ca2+ activity separately. Calcium transients in myocytes 
are typically measured using fluorescent Ca2+-binding dyes on a fluorescent 
microscope107.  
Satin et al. laid the groundwork using hESC-CMs108. They loaded cells 
with the dye Fluo-4 AM and recorded intracellular Ca2+ transients with a confocal 
microscope. Using this technique, they observed both entire-cell AP-driven 
transients, as well as localized SR Ca2+ release events (sparks). They then used 
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caffeine to mobilize Ca2+ release from the SR, as well as ryanodine to inhibit 
release from the ryanodine receptor RyR. They were able to provide evidence 
that hESC-CMs have large stores of Ca2+ in the SR, a hallmark of mature cardiac 
myocytes. Moving to iPSC-CMs, several labs106,109 have imaged Ca2+ transients 
and sparks in healthy cells by loading them with fluo-4 under a confocal 
microscope, and used caffeine to probe SR stores. Fura-4F, a ratiometric 
calcium dye, has been used to observe the propagation of Ca2+ transients 
through iPSC-CM monolayers, while simultaneously measuring intracellular 
voltage with the voltage-sensitive fluorescent dye, di-8-ANEPPS110. 
Using hiPSC-CMs derived from patients with catecholaminergic 
polymorphic ventricular tachycardia (CPVT), a genetic arrhythmic defect, 
differences were shown in Ca2+ handling in diseased versus healthy cells based 
on Fluo-4 fluorescent imaging111. Furthermore, they used voltage clamping to 
directly measure the L-type Ca2+ current (ICa) and the Na+–Ca2+ exchanger 
(INCX). A combined fluorescent Ca2+ imaging with voltage-clamped ICa 
measurement can also demonstrate changes in how iPSC-CMs handle Ca2+ as 
they mature112.  
Recently, Ca2+ handling characteristics across cells derived in different 
laboratories have been compared113, using the ratiometric Ca2+ dye Fura-2 AM 
and recording transients while the cells were electrically stimulated. Using 
caffeine, SR Ca2+ stores were estimated, and ICa was measured by whole-cell 
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patch clamp. Overall, there were comparable results between these laboratories. 
To summarize, iPSC-CMs have functional Ca2+ stores, and release and reuptake 
Ca2+ via the SR, and these events can be detected by Ca2+-sensitive fluorescent 
dyes such as a Fura or a Fluo derivative. 
 
Force Production in Stem Cell-Derived Cardiac Myocytes 
The most important parameter of a myocyte's function is its force 
production, as this determines how effectively the organ can circulate blood. An 
adult myocyte, with its well-organized sarcomeres and rectangular shape, can 
relatively easily be studied using video microscopy or force transducers114. In 
comparison, the morphology of a stem cell-derived myocyte presents some 
distinct challenges. Early on, groups used video edge detection to track 
movement of stimulated beating EBs as a percent of baseline length115. They 
were able to show increased contractility in response to β-adrenergic stimulation, 
a hallmark feature of cardiac myocytes. HiPSC-CMs derived by a monolayer 
method can also be monitored by video microscopy. Motion tracking software 
can be used to assess beating frequency, amplitude, and kinetics of a 3D tissue-
like construct formed by seeding iPSC-CMs onto a filamentous polymer matrix116. 
While video-based edge detection of contractility is very useful, the ability 
to measure force production against a load provides a more direct measure of 
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myocyte function. One approach to measuring force involves seeding beating 
clusters from iPSC-derived EBs onto 300 μm thin strips of neonatal murine 
ventricular myocardium, and then attaching the myocardial strip to force 
transducers for measurement102.  
Sun et al. used single cell-dispersed iPSC-CMs derived from a patient with 
dilated cardiomyopathy to assess single-cell force production using atomic force 
microscopy. This approach relies on the microscope for detecting changes in 
force at the cell surface caused by changes in stiffness within the cell, 
presumably due to rearrangement of sarcomeric and cytoskeletal proteins during 
contraction87. However, it should be noted that this is a technique that has not yet 
been validated in pluripotent cell-derived cardiac myocytes, neonatal cardiac 
myocytes, or adult myocytes. In the paper, the authors cite a paper exploring use 
of the technique on embryonic chicken cardiac myocytes, where the authors note 
that parameters such as beat period and pulse amplitude were observed to be 
unstable117. 
The micropost array, a technique that has been well validated in other 
myocyte cell types, has been used to measure contractile force of iPSC-CMs118. 
In this assay, an array of microposts is fabricated from polydimethylsiloxane 
(PDMS) using photolithography and the tops of the posts are coated with ECM 
proteins, and cells are seeded on top of that. As cells contract, the posts deflect 
with the cell, and video microscopy with subsequent analysis is able to convert 
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movement into force needed to move the microposts. The authors were able to 
examine different force production of cells that had been seeded on distinct types 
of ECM protein.  
In a similar vein, Sheehy et al. utilized the muscular thin film (MTF) assay, 
wherein thin strips of PDMS are fabricated and coated with ECM proteins. The 
iPSC-CMs are then seeded and stimulated119. As cells contract, the MTFs bend 
and curvature is analyzed with video microscopy, and force production is 
extrapolated from MTF displacement. These studies show that iPSC-CMs 
produce a force that is able to be measured; however, the techniques for force 
measurement are not well developed, and there is an urgent need for improved 
methods. 
Cardiac Myocyte Structure Contributing to Function 
The Sarcomere 
The main module of the myocyte that allows the cell to contract and 
produce force is the sarcomere. Sarcomeres connected in series form myofibrils, 
which run parallel to the long contractile axis of the cell. They are made up of 
thick filaments, which consist of myosin heavy chain and light chain and which 
are centered around the M line, and thin filaments, which consist of actin, 
troponin, and tropomyosin, and which connect at the Z disc, which contains 
sarcomeric actinin and several other proteins114. There are various other proteins 
involved, such as titin and nebulette, which control things such as Z disc spacing, 
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and which contribute to elasticity. During contraction, calcium released from the 
sarcoplasmic reticulum binds to troponin, which causes movement of 
tropomyosin, allowing myosin to bind to actin and myosin ATPase activity; 
myosin moves along actin, pulling Z discs nearer each other, resulting in 
contraction of the cell when all sarcomeres in the myocyte move 
simultaneously114.  
Actin 
Actin plays a crucial role in the contraction of the myocyte, as well as in 
cytoskeletal structure, cell morphology, membrane protein localization, and 
transduction of force from the sarcomere to the cell’s environment. Actin is a 
globular protein that can be found as a monomer (G actin) or a filamentous 
polymer (F actin), which forms following nucleation when G actin has ADP 
bound. F actin is dynamic, meaning that it is elongating at the (+) end and 
shortening at the (-) end, unless there are proteins to prevent growth or 
shortening, such as CapZ, which caps the (+) end. Otherwise, for an F-actin 
filament to remain a constant length, elongation and shortening must be in 
equilibrium120.  
In the thin filament, actin is of the isoform alpha-sarcomeric actin, coded 
for by the ACTC1 gene; although the sarcomere is a fairly constant length, actin 
dynamics and CapZ capping dynamics occur in response to physiologic stimuli 
such as exercise and mechanical stimulation, which increases dynamics121. 
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Levels of alpha-sarcomeric actin in the myocyte also influence hypertrophy and 
cell size, and are influenced by regulators of hypertrophy122. 
Actin in the cytoskeleton lives just below the cell membrane and plays a 
key role in maintaining and altering the size and shape of the cell, and in motility 
in motile cells, such as epithelial cells and leukocytes. In the cardiac myocyte, 
control of cytoskeletal actin dynamics has been shown to be crucial for cell 
hypertrophy and maintenance123. Furthermore, because of connections made 
between actin and some membrane-bound proteins including channels and 
receptors, cytoskeletal actin plays a role in subcellular localization of receptors 
and channels, as well as their functional state and open-closed status, allowing 
specific microenvironments to form within the cytoplasmic compartment with 
differential concentration of ions, signaling proteins, and cytoskeletal 
components124.  
Cytoskeletal actin, along with other cytoskeletal proteins, provide a crucial 
link between the cell membrane, extracellular proteins, and contractile proteins, 
and there is considerable evidence that changes in one of those compartments, 
such as changes in extracellular matrix proteins, contribute to changes in 
contractile protein expression, with actin as an important signaling protein125. 
Mechanosensing Mechanisms 
  41 
As all cells live in a physical environment with discrete three-dimensional 
spatial arrangements and constant, various physical forces being exerted on 
them, such as compression, stretching, or shear forces, it is crucial for cells to be 
able to respond appropriately to those stimuli, whether that entails building 
cellular structures that resist those forces, or building cellular structures that allow 
the cell to take advantage of or move with those forces, or possibly conversion of 
one cell type to another. This ability to sense requires a conversion of a 
mechanical signal to a chemical signal, and ultimately activation or inactivation or 
proteins through phosphorylation or other post-translational modifications or 
through gene upregulation or downregulation. Cells can do this through several 
methods, including mechanosensitive ion channels, which open and allow influx 
or efflux of a depolarizing or hyperpolarizing ion in response to a threshold 
stress126.  
Cells also utilize adhesions between the cell and its surrounding 
extracellular matrix, called focal adhesions; in myocytes, the costamere, or 
dystrophin-glycoprotein complex (DGC), which connects the contractile 
machinery of a striated muscle cell to the ECM, may also be involved. Focal 
adhesions contain proteins such as integrins, actin, filamin, vinculin, talin, and 
focal adhesion kinase (protein tyrosine kinase 2). In one well studied model of 
mechanosensing, ECM proteins form connections with integrins, which are 
transmembrane proteins with both extracellular and intracellular domains. 
Movement of ECM pulls on integrins, which activate talin or paxillin intracellularly. 
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Activation of paxillin can lead to activation of FAK, Rho- and ARF-GTPases, and 
the ILK/pinch/parvin complex. Talin is connected to cytoskeletal actin, which can 
activate the ILK/pinch/parvin complex, as well as membrane channels, or nuclear 
cytoskeletal proteins127. 
In a cardiac myocyte, mechanotransduction from the environment to the 
cell can open ion channels that can lead to stretch-induced arrhythmia, and can 
lead to upregulation and secretion of atrial natriuretic peptide128. Mechanical 
stress in the heart can come from various places including stretch due to 
increased ventricular or atrial blood volume, stiffness due to fibrosis and 
increased ECM deposits, or changes in the passive or active tension of 
neighboring cardiac myocytes. In the myocyte, other mechanosensing pathways 
than the focal adhesion pathways mentioned above come into play- opening of 
stretch-activated calcium channels creating calcium influx, which can in turn 
cause calcium-induced calcium release (CACR); or activation of Angiotensin II 
release, which feeds back by binding to AT receptors on the myocyte surface. 
Activation of these pathways in the myocyte can lead to altered gene expression, 
fibrosis, and cell and organ hypertrophy129.  
 
Force Transmission from the Cell to the Environment 
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The production of force by a cell on its environment is in some ways the 
reverse of mechanosensing- the cell must create an internal force that is 
transferred to its environment. In motile cells, such as migrating cells during 
embryonic development, or during dendritic or axonal growth of neurons, or in 
non-motile contractile cells such as myofibroblasts or endothelial cells whose 
contraction depends on stress fibers, this transmission of force occurs at the 
focal adhesion, through the actin-integrin-extracellular protein connection. It 
depends to a significant extent on actin motility130 and relies on feedback from 
both stretch-activated channels and mechanotransduction through the same 
focal adhesions131. 
In the myocyte, transmission of force from the sarcomere to the 
environment depends on lateral transmission through the costamere132. There 
are several steps in between- first, sarcomeric actin pulls on actinin in the Z disc; 
actinin transmits this force to the major intermediate filament protein holding Z 
discs together- in the adult cardiac myocyte this is desmin, although in the 
developing cardiac myocytes and in immature cardiac myocytes this is vimentin, 
which has different biophysical properties than desmin133.  
Disruption of desmin during extreme mechanical stress also plays a role in 
sarcomerogenesis and myofibrillogenesis, leading to cardiac myocyte 
hypertrophy134. Desmin can transmit force to a number of protein complexes at 
the cell membrane including focal adhesions; spectrin, ankyrin, crystallin, sodium 
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channels, and Na-K ATPase; and the DGC. The DGC includes proteins such as 
the transmembrane proteins sarcoglycan and dystroglycan, the extracellular 
protein laminin, and intracellular proteins dystrobrevin, syntrophin, plectin, 
utrophin, and dystrophin, which have roles in structural support, modulation of 
force transmission, and maintenance of cell and membrane elasticity and 
integrity132. 
Force Production in the Cardiac Myocyte 
Contributors to Contractility- Calcium 
When it is necessary for the cell to produce more or less force, modulation 
of contractility takes place. A cell producing more force against the same 
mechanical load will contract more in terms of length of shortening, and a cell 
with more sarcomeres will produce more force than a cell with fewer sarcomeres, 
if the individual sarcomeres are producing equal amounts of force. On the 
sarcomeric level, increasing contractility requires increasing activation and 
recruitment of filaments; meaning, more frequent attachments between myosin 
and actin. Since this attachment relies on troponin moving tropomyosin away 
from actin so that myosin can bind, increased contractility can be achieved either 
through increased calcium, which binds to troponin C and activates the complex, 
or through increased phosphorylation of the troponin complex. Increased calcium 
can occur through increased flux across the cell membrane through the L-type 
calcium channel (LTCC; dihydropyridine receptor DHPR), increased release from 
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the sarcoplasmic reticulum; or decreased uptake into the sarcoplasmic 
reticulum135.  
The amount of calcium released from the SR depends largely on the 
amount loaded into the SR during diastole through the 
Sarcoplasmic/endoplasmic reticulum ATPase (SERCA). SERCA activity is 
regulated by phospholamban (PLN); binding of PLN inhibits SERCA function, but 
when it is phosphorylated it exists in a pentameric state and cannot inhibit 
SERCA. Thus, adrenergic signaling acting through PKA and cAMP inhibits PLN 
and increases SERCA activity, thereby increasing contractility through increased 
calcium. PKA also increases the open probability of ryanodine receptors (RyR), 
which release calcium from the SR into the cytoplasm136. Several drugs aimed at 
improving cardiac function take advantage of this by inhibiting phosphodiesterase 
(PDE), which breaks down cAMP137. There is also good evidence for a role in 
myosin binding protein C (MyBP-C) in cardiac contractility. MyBP-C associates 
with the thick filament; it has PKA phosphorylation sites, and affects crossbridge 
cycling kinetics138. 
Contributors to Contractile Kinetics- Troponin 
While absolute force production is important to a myocyte’s function, 
contractile kinetics are also important- a heart that beats faster must contract and 
relax faster in order to maintain ejection fraction and increase cardiac output. 
Increasing the number of activated SERCA pumps through regulation of PLN can 
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increase the rate of removal of calcium from the cytoplasm, shifting the 
equilibrium of unbound calcium and calcium bound to TnC towards the unbound 
side and increasing the rate of deactivation of troponin and detachment of 
myosin from actin135. We have also noted that MyBP-C and its phosphorylation 
through the adrenergic-PKA pathway plays a role in crossbridge kinetics138. 
Phosphorylation of the troponin complex, such as troponin I, by PKA and 
adrenergic signaling, also plays a very significant role in a sarcomere’s ability to 
contract and relax quickly in response to sympathetic activation. Of note, 
phosphorylation of troponin I enhances the speed of both contraction and 
relaxation139. 
The isoform of troponin I expressed also influences contractility kinetics; 
cardiac troponin I (cTnI), which is expressed in adult cells, is faster than slow 
skeletal troponin I (ssTnI), which is expressed in immature cells. However, ssTnI 
is a positive inotrope, especially under acidic/hypoxic conditions, and has 
increased calcium sensitivity, although it lacks the PKA-mediated 
phosphorylation site that causes calcium desensitization in cTnI. Mutant 
isoforms, and engineered isoforms, of TnI can enhance or diminish some of 
these characteristics. Importantly, the A164H isoform of cTnI, where the alanine 
and position 164 is replaced with a histidine, maintains the increased lusitropic 
effects of cTnI, while rendering the protein more resilient to acidotic/hypoxic 
conditions140. 
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Contributors to Contractility- Mechanical Load 
The heart alters contractility in response to mechanical loads, while 
attempting to maintain homeostatic levels of cardiac output.  The heart as an 
organ experiences two types of mechanical load- preload and afterload. Preload 
affects the amount of stretch of cardiac myocytes before systole, and the amount 
of passive tension that the cardiac myocytes experience, and encompasses all 
the factors that contribute to passive wall stress, including end-diastolic volume, 
central venous pressure, end-diastolic filling pressure, chamber wall thickness 
and wall compliance. Afterload affects the amount of active tension that a cardiac 
myocyte must generate in order to produce sufficient cardiac output, and 
encompasses the factors that contribute to wall tension during systole, including 
systolic volume, systolic pressure, chamber wall thickness, outflow tract 
resistance, and systemic arterial resistance (systolic arterial pressure, diastolic 
arterial pressure, arterial compliance)141.  
In order to maintain adequate cardiac output, cardiac myocytes must 
appropriately respond to preload and afterload; by using the mechanosensing 
pathways noted above, a cardiac myocyte increases contractility in response to 
increased preload (increased stretch and sarcomere lengthening142. In response 
to increased afterload, cardiac myocytes may increase contractility due to 
adrenergic signaling through the sympathetic nervous system, or, through 
mechanosensing, cells may automatically increase force production in order to 
maintain equivalent contractile amplitude142. 
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Measuring Contractility in Stem Cell-Derived Cardiac Myocytes 
Traction Force Microscopy 
In order to explore these aspects of contractility and response to load in 
hiPSC-CMs, an appropriate assay is needed. The total force produced by an 
adult cardiac myocyte can be measured using piezoelectric force transducers; 
the unique geometry and dense sarcomeric protein structure allows quantification 
of a precise nature143. Contractile kinetics of an adult cardiac myocyte can be 
measured optically, by tracking sarcomere length and shortening, taking 
advantage of regular light-dark patterns of registered sarcomeres; this can be 
done on the same force transduction apparatus, or on a modern system such as 
the Ionoptix 144. These assays have so far been poorly suited to use in iPSC-
CMs.  
Traction force microscopy is a valuable method that utilizes the known 
mechanical properties of a deformable substrate coupled with high-resolution 
microscopy to accurately measure the developed force of contractile or motile 
cells.  Traction force microscopy allows investigation of the physiologic function 
of a single isolated hiPSC-CM by measuring force produced by a single cell 
against a load produced by a stiff substrate. Measuring the force of a single cell, 
rather than a sheet of cells, allows rigorous determination of the effects of cell 
geometry on contractility, and removes several potentially confounding effects 
that might come from sheet-based assays, including number of cells, relative 
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orientation of cells to each other, and presence of non-cardiac myocyte cell types 
that may have differentiated in culture alongside the myocytes.  
Traction force microscopy has been utilized to measure the amount of 
stress produced by cells including fibroblasts145, keratocytes146, osteoblasts147 
and NRVMs148 and has been used to calculate the strain energy, which is the 
energy required to deform a material149. Determining stress and strain energy in 
response to changes in substrate stiffness allow modeling of both increased 
stiffness changes that may occur in the heart under various conditions, as well as 
changes in afterload that ventricular myocytes experience during systole under 
conditions of valvular disease or increased systemic mean arterial pressure. 
The rigorousness and versatility of traction force microscopy also allows 
examination of the effects of other influential factors in the development and 
differentiation of cardiac myocytes. For example, one can look at the effects of 
prolonged time in culture on contractility and morphology, or the effects of 
extracellular calcium concentrations, as it has been recently shown that calcium 
concentrations play a vital role in the development and hypertrophy of cardiac 
myocytes during development150-151. Taken together, traction force microscopy 
provides a reliable and rigorous method of determining contractile force of iPSC-
derived cardiac myocytes. 
 
Traction Force Microscopy- Methodology 
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The technique begins with micropatterning stamps152. Single cell shapes 
are placed far enough apart to ensure contraction of one cell would not affect 
substrate deformation of neighboring cells. Stamp masters are created using 
photolithography by applying photomasks to silicon wafers coated with 
photoresist and exposing to light. Stamps are created by curing 
polydimethylsiloxane (PDMS) on the patterned silicon master (for patterned 
stamp) or on an unpatterned silanized silicon wafer (for blank stamps). Both 
patterned and unpatterned stamps are made new each time they were used. 
Stamps are coated and stamped according to the stamp-off protocol laid out by 
Desai et al153. Briefly, blank stamps are coated with laminin (50 µg/ml in 
molecular biology grade water) and incubated for 60 minutes, then dried and 
inverted onto patterned stamps which have been UV-activated. Blank stamps are 
immediately peeled off and placed onto 15 mm coverslips which have been 
plasma-activated by running through a blue flame. Cover slips are then ready for 
use with gels. 
Polyacrylamide gels are made using ratios of Acrylamide to N,N’-
methylenebisacrylamide that allow various substrate stiffness to be examined154. 
Ahead of time, 25 mm glass coverslips were UV treated, then treated with 3-
aminopropyltriethoxysilane for 3 minutes, and rinsed with ethanol. 
Polyacrylamide was made with 1x phosphate-buffered saline, and 0.2 µm 
fluorescent beads are mixed into the unpolymerized acrylamide solution. 
Ammonium persulfate and N-hydroxysuccinimide ester are added to solution. 
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Laminin-coated coverslips are inverted onto the solution and allowed to 
polymerize. hiPSCs are dissociated and replated onto polyacrylamide gels. Cells 
adhere overnight, then assayed on day 3 after plating.  
Images of fluorescent beads moving within the substrate that the cells are 
exerting a stress on are acquired using a high-resolution microscope at the 
fastest rate possible while still acquiring images suitable for analysis. Cells can 
be paced in the single cell state, or allowed to pace at their intrinsic rate, 
although pacing cells allows for rigorous comparison of cells at the same 
frequency and voltage. Images may be analyzed using any suitable TFM 
analysis software, though many people are using ImageJ code developed by 
Tseng et al155-156.  
Stacks of images of the cell and fluorescent beads before and during 
contraction are compared; the software calculates a displacement field using a 
particle image velocimetry program, by comparing movement of areas of 
interrogation with surrounding areas. It then calculates stress vectors from 
displacement vectors using the Fourier transform traction cytometry method157. A 
smoothing parameter of 1x10-9 may be applied for improved accuracy, as 
described in Stricker et al158. Stress vector magnitudes may be integrated over 
the area of interest and reported as total force. Strain energy can be calculated 
according to the equation laid out in Oakes et al149, by taking the integral of the 
product of the displacement and traction stress vectors of each cell. 
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Traction Force Microscopy on Stem Cell-Derived Cardiac Myocytes- 
Current Understandings and Results 
At least two or three research groups have performed this assay on 
hiPSC-CMs, with differing results. Most follow the steps listed above with slight 
variations in their protocols; they share themes of micropatterning and isolated 
cardiac myocytes, but they choose to examine the effects of different conditions 
of contractility and force production. One group focused heavily on the 
quantitative aspects of the data analysis; they show that iPSC-CMs have 
contractile curves with similar shapes to those of adult cardiac myocytes. They 
also increased force in response to isoproterenol, and decreased force in 
response to verapamil, which blocks the LTCC. They also use the assay to show 
cardiotoxicity of the known cardiotoxic drug dofetilide159.  
Other researchers have used the assay to show that force production 
increases with increased time in culture; they also showed a weak response to 
isoproterenol on soft substrates but not stiff ones160. In this paper, they showed 
that force increases as cells are plated on increasingly stiff substrates, although 
in their next paper they show the opposite. A collaborating group showed that 
higher aspect ratios (7:1 vs 3:1 or 5:1, which is the ratio of the length of the long, 
contractile axis over the short, perpendicular axis) produce higher force, 
presumably due to increased myofibril orientation161. 
 
Gene Expression Throughout the Life of a Cardiac Myocyte 
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Gene Expression and Isoform Switching in Fetal Development 
During the cardiac development process, as has been described in detail 
above, there are significant changes in the genes that are expressed, and 
particularly in differential expression of isoforms of proteins, such as sarcomeric 
proteins myosin heavy chain (MHC) and troponin I (TnI), as well as in beta-
adrenergic receptors, ion channels, and transcription factors; there are also 
changes in the localization of some of these proteins. In striated muscle, there 
are three isoforms that are transcribed from three separate genes in a muscle 
fiber type-specific manner162-164. These isoforms are fast skeletal troponin I 
(fsTnI/TNNI2), expressed in fast skeletal muscle fibers; slow skeletal troponin I 
(ssTnI/TNNI1), expressed in slow skeletal muscle fibers and fetal cardiac muscle; 
and cardiac troponin I (cTnI/TNNI3), expressed only in adult cardiac muscle. 
SsTnI and cTnI are the two key myofilament isoform proteins in the cardiac 
myocyte and are antithetically expressed during the transition from fetal to adult 
life164-165.  
The ssTnI isoform is expressed during neonatal or fetal life and is then 
stoichiometrically replaced by the cTnI isoform, which is exclusively expressed in 
mature adult cardiac myocytes164-169. The cTnI isoform has a unique N-terminal 
extension containing serine residues that are phosphorylated in response to 
adrenergic stimulation of the heart, making it PKA-responsive. This PKA 
responsiveness is critically required for the fast relaxation that is necessary for 
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optimal adult cardiac function139,170-171. Thus, acquisition of this key adult 
signature maturation marker by hiPSC-CMs is indispensable.  
Cardiac myosin has two cardiac myosin light chain 2 (MLC2) isoforms, 
MLC2a and MLC2v. In the developing human and mouse heart, MLC2a 
expression is detected in all chambers172. In the postnatal heart, MLC2v is 
confined to the ventricle, and this chamber specificity persists to adulthood172-173. 
MLC2v expression is also considered to be a marker of cardiac myocyte 
maturity. Thus, several groups have used the expression patterns of MLC2a and 
MLC2v to define cardiac myocyte identity and stages of development.  
hiPSC-CMs primarily express MLC2a at early time points; at later time 
points, expression of MLC2v increases and expression of MLC2a decreases, 
with the majority of hiPSC-CMs co-expressing both MLC2a and MLC2v174. Here, 
hiPSC-CMs expressing MLC2v most likely represent ventricular-like cells, while 
those expressing MLC2a may represent a range of immature cardiac myocytes, 
including atrial-like cells. Earlier reports demonstrated prevalent MLC2v/MLC2a 
double-positive cardiac myocytes, with disorganized sarcomeres and weak 
hERG channel responses, to be immature, resembling human fetal cardiac 
myocytes175. 
 
Changes in Gene Expression During Heart Failure 
During heart failure, there are significant changes in gene expression, 
including some reversions to fetal gene expression. Many genes that encode for 
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contractile proteins have a characteristic pattern of expression during 
development, and many of these are also altered by disease conditions176. The 
failing heart reactivates fetal genes and reverts to a fetal pattern of energy 
substrate metabolism176-177. For instance, in mice, levels of fetal genes such as 
ANP, BNP, βMHC, skeletal actin, and metabolic genes such as GLUT1 are 
reactivated in the failing adult heart176-178. Moreover, αMHC, SERCA2a, ion 
channels, and metabolic genes such as GLUT4 are reduced during heart 
failure178-179. So, based on what is understood about cardiac development and 
the key proteins in cardiac function, this thesis focuses on three major proteins: 
TnI, MHC, and SERCA2a. 
Crucial Genes for Cardiac Development and Function 
Troponin 
Troponin exists in a complex of three distinct proteins- inhibitory troponin I 
(TnI), troponin C (TnC), and troponin T (TnT), which binds tropomyosin. In the 
activated state, calcium binds to troponin C, causing a conformation change, 
moving TnI and tropomyosin away from actin so that myosin can bind. During 
diastole, when calcium is taken back up into the SR, the troponin complex 
returns to its inhibitory state, releasing myosin from actin and causing relaxation. 
TnC has a fast isoform (TNNC2 gene) and a slow isoform (TNNC1 gene); 
cardiac muscle only expresses the slow isoform, though skeletal muscle 
expresses both, and there is no developmental switch180. Troponin T has a slow 
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skeletal (TNNT1), cardiac (TNNT2), and fast skeletal (TNNT3) isoform, and there 
is a possibility that cardiac muscle may express some slow skeletal TnT181. As 
noted above, TnI exists in slow skeletal, fast skeletal, and cardiac isoforms. The 
mutant A164H isoform shows increased calcium sensitivity in the face of hypoxia 
or hypercapnia by a histidine in the switch region between actin binding and TnC 
binding domains182. 
Myosin 
Myosin heavy chain is part of the myosin group of proteins; it falls under 
myosin class II, which contains 15 members. It has three domains- a head, which 
binds actin; a neck, which acts the main force transducing domain; and a tail, 
which binds other myosins, including a regulatory MLC and an essential MLC. 
During systole myosin goes through crossbridge cycling; in the relaxed state 
ADP and inorganic phosphate (Pi) are bound to the myosin head, which allows it 
to bind actin when troponin is activated, forming a crossbridge. When it releases 
ADP and Pi, the myosin head bends forward producing a power stroke and 
contraction; when ATP binds to myosin it releases from actin, the myosin 
ATPase function breaks down ATP into ADP and Pi, and the cycle can start over, 
or the filament can relax183. In cardiac myocytes, there are two isoforms 
expressed; the alpha isoform has 3-fold higher ATPase activity and higher actin 
filament sliding velocity. It is expressed at low levels in the adult heart, but not in 
the developing heart, and cardiac disease such as heart failure and myocardial 
infarction decreases expression, though this may be somewhat reversed with 
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exercise. Expression is dependent on activation of thyroid hormone receptors184. 
The isoform of MHC expressed has significant effects on the function of troponin 
as well185. 
SERCA 
As has been noted above, SERCA2a, the dominant isoform of SERCA 
expressed in cardiac myocytes, plays a key role in cardiac contractility, e.g. in the 
amplitude of contractility, by regulating the amount of calcium taken up into the 
SR during diastole. Phospholamban inhibits SERCA ATPase activity, and 
phosphorylation of PLN increases SERCA activity78. Sarcolipin regulates SERCA 
activity in atrial myocytes but not ventricular186. Thyroid hormone upregulates 
SERCA expression and decreases PLN inhibition of SERCA, and adiponectin 
enhances SERCA activity, presumably by relieving oxidation and causing free-
radical scavenging, since free radicals inhibit SERCA function187. SERCA can 
also be glutathionylated or SUMOylated, both of which enhance function; 
glycosylated or O-glcNAcylated, both of which decrease function; or acetylated or 
nitrosylated, which have unknown effects on function and protein amount187.  
It is also known that heart failure decreases expression of SERCA, and 
exercise increases expression of SERCA, and there have been attempts to 
increase SERCA expression levels or decrease SERCA inhibition for therapeutic 
purposes187. It is also known that calcium handling is crucial for the development 
of cardiac myocytes, and that the amplitude and kinetics of intracellular calcium 
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transients change as cells mature, along with a shift from dependence on T-type 
calcium channels to L-type calcium channels, decreased NCX expression with 
greater dominance of Forward NCX mode, decreased response to calcium, 
increased buffering of cytosolic calcium due to increased TnC, and increasing 
SERCA expression which is paralleled by increasing SR calcium content188. 
 
Hypertrophy as a Marker of Cardiac Development and Contractility 
Pathways to Hypertrophy 
Hypertrophy is a key marker of various intracellular processes, both 
physiologic and pathologic. In a cardiac myocyte, hypertrophy essentially means 
an increased overall number of sarcomeres, although this does not always 
translate to increased force if other pathological factors are involved. There are 
several major pathways involved in cardiac myocyte hypertrophy; most of them 
are interconnected in some way, with significant cross-talk between pathways; 
some involve calcium signaling and proteins with calcium-binding sites, such as 
the nuclear factor of activated T-cells (NFAT)/calcineurin pathway, and the 
calcium/calmodulin-dependent protein kinase II (CaMKII) pathway, making them 
significant for cardiac myocytes which rely on calcium handling for physiologic 
function and which display altered calcium handling in development and 
pathology189. 
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In the calcineurin/NFAT pathway, activation of calcineurin, either through 
calcium binding or through non-calcium-mediated mechanisms such as direct 
binding of the sodium/hydrogen exchanger (NHE)190 leads to dephosphorylation 
of NFAT and translocation from the cytoplasm to the nucleus, where it interacts 
with other transcription factors such as NFκB to enhance expression of genes 
associated with hypertrophy, such as sarcomeric and cytoskeletal genes191. This 
pathway can be activated by signals such as testosterone189, Angiotensin II192, 
and beta-adrenergic signaling mediated by GPCR Kinases (GRKs)193. Sustained 
levels of increased calcium concentrations in myocytes has been shown to be 
mediated through transient receptor potential cation channels (TRPC channels), 
which are mechanosensitive and may be activated in pressure overload 
situations194. 
CaMKII is an important signaling molecule in cardiac myocytes, in that 
activation and upregulation of it leads to arrhythmia and cardiomyopathy, 
suggesting a role in homeostasis of ionic function, and leading to interest in it as 
a therapeutic target, although a role for CaMKII in the healthy heart has yet to be 
definitively found195. It is activated by calcium, although phosphorylation of the 
autoinhibitory site allows it to be active in the absence of calcium and calmodulin, 
and it can form hexameric structures that can autophosphorylate196. It depends 
on activation by calmodulin, which is a 4 EF-hand containing calcium-binding 
protein that is expressed in all eukaryotic cells197.  
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CaMKII can phosphorylate calcium-activated potassium currents198, 
ryanodine receptors199, and sodium channels200, and can be triggered by 
oxidative stress201. CaMKII can alter transcription of hypertrophy-associated 
genes by phosphorylating histone deacetylases HDAC4 and 5, exporting them 
out of the nucleus and inhibiting their inhibition of hypertrophic transcription 
factors such as MEF2, and CaMKII can work in tandem with calcineurin24. 
CaMKII can also interact with the MAPK/ERK pathway by phosphorylating ERK, 
and it has been shown that targeting CaMKII for inactivation can ameliorate 
pathologic hypertrophy and heart failure in some animal models202. 
Other paths to hypertrophy exist in the cardiac myocyte, which are not 
specific to the cardiac myocyte and have often been studied in more depth in 
other cell types; for example, the mitogen activation phosphatase (MAPK)/ERK 
pathway, which can be activated by growth factors, and can interact with NFAT, 
as well as MEK1 and GATA-4 and MEF2203. The mToR/Akt pathway is involved; 
here mToR is a downstream target of Akt (protein kinase B), which activates 
protein synthesis and inhibits autophagy, but is inhibited by low levels of ATP 
through AMP Kinase194. This pathway can be activated by such diverse signals 
as insulin, cholesterol204, inflammation205, and angiotensin II206. Finally, sirtuins 
(SIRT) play a role, including SIRT3 and SIRT6 which inhibit hypertrophy by 
acting through Akt, and SIRT1 which has a more complex role207. 
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Pathologic versus Physiologic Hypertrophy 
The differences between pathological organ hypertrophy and physiological 
organ hypertrophy can be seen clinically; for example, a patient with pathological 
left ventricular hypertrophy has impaired diastolic ventricular filling, including 
delayed relaxation and a decrease in maximal early velocity of diastolic filling, 
while a patient with physiological hypertrophy has normal filling patterns208. 
Tissue Doppler also shows decreased systolic velocities in patients with 
pathologic hypertrophy, but not in athletes with physiologic hypertrophy209. 
Molecular and cellular differences are less well-known; but several genes are 
associated with pathologic but not physiologic hypertrophy- for example, BNP, 
angiotensin converting enzyme (ACE) and vascular cell adhesion molecule-1 
(VCAM1) are overexpressed in pathologic hypertrophy but not exercise-induced 
physiologic hypertrophy210. 
 
Genome Editing to Induce Cardiac Myocyte Maturation 
Early Technological Developments 
In order to induce expression of these proteins of interest, which are 
crucial in the development, maturation, and physiologic function of cardiac 
myocytes, this project takes advantage of a fairly recent technological innovation 
known as genome editing. Before genome editing, expression of a particular 
gene or protein relied on viral vectors, which come in many flavors and are still 
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extremely useful- some viruses are able to express genes transiently, such as 
adeno-associated virus (AAV); some viruses are able to express genes for 
several months to years, such as adenovirus (AV); some viruses are able to 
integrate into the host genome and express genes long-term, such as 
lentivirus211. Issues with viral delivery include short expression times, limited size 
of DNA that viruses are able to carry, host immune response, lack of viral 
receptors on target cells, or random integration of genes into potentially 
disruptive sites in the host genome. There also exist other technologies and 
means of introducing nucleic acids into cells, such as engineered nanoparticles 
that can carry DNA or RNA into the host cell; these also result in short periods of 
expression212. 
Genome editing, however, utilizes enzymes that make either double- or 
single-stranded breaks at very precise locations in the genome of the host cell- 
this allows the cell to repair it the DNA using non-homologous end-joining 
(NHEJ), which may lead to nullification of the gene, or, if a template is provided, 
the cell may use homology-directed repair (HDR), which may lead to the cell 
incorporating the template-provided sequence into the genome permanently- this 
can be used for short changes in the sequence of a gene, including single-
nucleotide changes, or for introduction of entire genes and promoters213.  
The earliest technology used for this was zinc-finger nucleases (ZFNs), 
used since the early 2000s, which are restriction enzymes engineered to 
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recognize a specific DNA sequences through the zinc finger domain of the 
protein, and can recognize longer sequences of bases when zinc finger domains 
are tandemly repeated; a ZFN with four fingers can recognize a 24-bp sequence. 
They contain a FokI domain for DNA cleavage. ZFNs suffer from a need for 
selection of specific binding domains for a given sequence, rather than the ability 
to engineer it exactly- they rely on bacterial selection to find the most specific 
sequence, which can be a lengthy process213. 
Following on the success of ZFNs, several researchers began engineering 
DNA-binding enzymes using transcription activator-like effectors (TALEs), 
proteins from a bacterial plant pathogen Xanthomonas, which bind specific 
sequences of DNA using domains that are essentially loops with two amino acids 
at the outside of the loop that bind a particular base; so that up to 18 loops in a 
row will bind a sequence of 18 amino acids214. By attaching a FokI domain for 
nuclease activity, a TALEN is created, and TALENs can be used to efficiently 
cleave genomic DNA- they require two TALENs, one on either side of the 
cleavage site, for FokI to activate, thus improving specificity215.  
TALENs are more easily engineered than ZFNs, with a higher rate of 
success, and with comparable mutagenesis216. Protocols and kits for rapidly 
building locus-specific TALEN cDNA using bacterial cloning have also been 
developed217-218. TALENs have advantages of being modular, easy to use, and 
effective; they suffer from the fact that because each nucleotide is recognized by 
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an entire protein domain, the cDNA can be large ~3 kb compared to ~1 kb for a 
ZFN, potentially inhibiting its ability to be packaged into a viral vector or 
transfected into a cell215.  
Recent Developments: CRISPR/Cas9 
The most recent advance in genome editing has come in the form of 
clustered interspace short palindromic repeats (CRISPR) and CRISPR-
associated systems (Cas); these are bacterial defense systems that have been 
discovered in several species of bacteria, including Streptococcus pyogenes and 
Neisseria meningitides. They are comprised of a strand of mRNA that recognizes 
the locus of interest, and an enzyme with nuclease activity that binds the mRNA 
(guide RNA, gRNA) and cleaves the DNA at that site219.  
The CRISPR system has the advantages of being smaller than TALENs, 
and thus more deliverable, as well as faster and cheaper to engineer and build, 
so that several gRNAs can be tested against a particular locus to find the one 
with highest cleavage efficiency and fewest off-target effects. Additionally, many 
modifications to the Cas enzyme have been made- some optimization has been 
done in order to improve efficiency, but modifications have also been made that 
reduce nuclease activity to a single strand, or abolish it completely so that the 
system acts as a way of guiding transcription factors to the locus, or they have 
been used as designer transcription factors or repressors220. 
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Genome Editing in Stem Cells and Stem Cell-Derived Cardiac Myocytes 
Disease Modeling 
Genome editing as a way of permanently altering genomic DNA has been 
used and envisioned as a way of more effectively modeling certain diseases, 
either by making precise deletions, insertions, or point mutations to model 
genetic disease; by long-term overexpression or deletion in cell lines, including 
stem cells and stem cell-derived cells; or by efficient editing of animal model 
genomes to produce animal models more rapidly and without potentially 
disruptive random insertion of genes into the genome221. For example, TALENs 
have been used to model Hemophilia A in iPSCs by creating an inversion in the 
factor VIII gene, a genotype which is commonly seen in Hemophilia A patients, 
and furthermore, TALENs were able to correct that same inversion222. ZFNs were 
used to remove GAA repeats from the frataxin gene (FXN), since GAA repeats in 
that gene are the genotype associated with Friedrich’s Ataxia; when these cells 
were differentiated into neuronal cells, the Friedrich’s Ataxia phenotype was 
reversed, with rescued expression of frataxin223.  
In the field of cardiovascular disease, genome editing has been used to 
model Long QT syndrome; one group used ZFNs to insert voltage-gated 
potassium channels KCNQ1 and KCNH2 with dominant-negative mutations into 
the AAVS1 safe-harbor site of iPSC-derived cardiac myocytes. Their edited cells 
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displayed characteristic phenotypic markers including prolonged action potential 
duration and amelioration with LTCC blocker nifedipine224. As noted in their 
paper, isogenic genome editing allows edited cells to be compared with 
nonedited cells that have the exact same genetic background, thus removing 
potentially confounding factors of SNPs and mutations found elsewhere in the 
genome, meaning that phenotypic changes are due to the genomic edit alone. 
Elsewhere, a group has used TALENs to introduce a mutation in PLN to iPSC-
CMs in order to recapitulate dilated cardiomyopathy (DCM) associated with that 
mutation, and then TALENs were used to isogenically correct it as well. They 
showed that cells edited to contain the mutation produced low amounts of force, 
similar to cells from patients already harboring the mutation, which was corrected 
with isogenic correction225. 
Genome Editing for Therapeutic Purposes 
Beyond modeling, genome editing has begun to be studied for use in 
therapeutic settings, including cell therapy. The immunology world has quickly 
moved to take advantage of this, with the hopes of altering immune cells that can 
be phoresed from the patient’s blood, edited, and then re-transplanted back into 
the patient. A popular strategy has been the engineering of T cells to express 
chimeric antigen receptors (CARs) that recognize epitopes specific to cancer 
cells226. Many groups have continued down the path of gene editing from merely 
expressing CARs to downregulating or modifying other proteins and pathways 
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that interfere with the efficacy of CARs, such as the elimination of endogenous T 
cell receptors (TCRs)227.  
In the world of cardiovascular and muscular disease, Duchenne muscular 
dystrophy (DMD) has been an attractive target for genome editing. Several 
groups have explored using it in animal models or cell-based models to not 
correct the underlying mutation, but to excise entire groups of exons in a way that 
allows a truncated but still functional dystrophin protein to be expressed, thereby 
allowing a single set of nucleases to be effective against a group of patients with 
a range of different mutations228-229. It has been used to correct mice with the 
arrhythmic PRKAG2 cardiac syndrome phenotype by packaging the 
CRISPR/Cas9 system into AAV9 vectors to disrupt the mutant allele while 
leaving the healthy allele intact, leading to improved phenotype230.  
Conclusions 
There is significant room for growth and improvement in the fields of 
cardiovascular disease, stem cell biology, iPSC-CMs, and genome editing for the 
use of disease modeling and cell therapy. Cardiovascular disease, including 
congestive heart failure with its myriad of contributing and precipitating factors, 
remains a significant problem in the developed world and is becoming more of a 
problem in the developing world. Stem cells, including induced pluripotent stem 
cells, and cardiac myocytes derived from them have shown enormous potential 
in the treatment and research of cardiovascular disease, although there remain 
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important barriers to using them fully, including their immature physiological 
function, lack of adequate physiologic assays to probe their function, and 
immature gene expression profile.  
This thesis uses several cutting-edge technologies, including traction force 
microscopy and genome editing, to rigorously measure hiPSC-CM function under 
important conditions such as increased mechanical load and altered extracellular 
ionic concentrations. Furthermore, this thesis explores attempts to alter the 
isoforms of crucial proteins expressed, including calcium handling proteins and 
mature isoforms of sarcomeric proteins, in order to affect physiologic function 
including calcium handling and contractile kinetics, and to ultimately affect the 
gene and protein expression profile in a cell-wide level. 
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Abstract 
 
Recent technological advances have made it possible to efficiently derive 
cardiac myocytes from human induced pluripotent stem cells (hiPSC-CMs). 
These have been seen as a model for human heart disease, as well as a 
potential source for cellular transplantation into failing diseased heart tissue. 
Many laboratories have devoted substantial effort to examining the functional 
properties of hiPSC-CMs, including electrophysiology, intracellular calcium 
handling, and gene/protein expression and force. Here we utilize traction force 
microscopy (TFM) to determine the maximum force production of isolated hiPSC-
CMs under varied culture and assay conditions. We elucidate here the 
relationship between cell morphology and force production, HiPSC-CMs 
developing in culture for two weeks produce significantly less force than cells 
cultured from one to three months and hiPSC-CMs cultured for three months 
resemble the cell morphology of neonatal rat ventricular myocytes. hiPSC-CMs 
produce less force when assayed on increasingly stiff substrates, and generate 
less strain energy. Finally, hiPSC-CMs cultured in conditions of physiologic 
calcium concentrations are larger and produce more force than cells cultured in 
standard media. Collectively, these findings establish single cell TFM as a 
valuable approach to illuminate the quantitative physiological maturation of force 
in hiPSC-CMs. The demonstration here of an inverse relationship between force 
and substrate stiffness has implications for translating hiPSC-CMs into ongoing 
efforts to remuscularize diseased myocardium in vivo.  
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Introduction 
 Over the past several years it has become possible to efficiently derive 
from human induced pluripotent stem cells (hiPSCs) robust spontaneously 
contracting cardiac myocytes (hiPSC-CMs)65-66,231. Regarded as a potential 
source of virtually unlimited human cardiac muscle tissue, researchers and 
clinicians have begun utilizing these hiPSC-CMs as sources of therapeutic cell-
based repair via transplantation into host63 and for cellular and tissue models of 
cardiac disease 232-233. Since their discovery, considerable efforts have been 
underway to assess and quantify hiPSC-CM contractile function and 
development using culture conditions that may better mimic the physiological 
cues imposed on native cardiac cells and tissues in vivo. Importantly, substantial 
effort has been made to address the developmental state and physiological 
maturity of the hiPSC-CM112,174,234. 
 The central measure of the physiologic function of a cardiac myocyte, and 
the essential purpose of the cell, is force production. To date, several groups 
have optimized assays to measure force production of hiPSC-CMs, either as a 
syncytium102,235 or population of cells on a thin film148, or as single cells using 
micropost arrays236 or using traction force microscopy160.  Specific force 
production is an important quantitative index of cardiac myocyte maturity but thus 
far has been difficult to ascertain in hiPSC-CMs. It has been shown that human 
fetal cardiac myofibrils have low force compared to adult cardiac myofibrils, and 
that this increases over time in human development69.  Furthermore, isometric 
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force in skinned myocytes from mice and sheep increase as gestational age 
increases237-238.  
 Closely related to the myocyte’s ability to produce force is its morphology, 
including total cell area, length and width. The use of micropattern printing to 
manipulate the shape of neonatal ventricular cardiac myocytes, shows a range of 
aspect ratios that result in maximal force production, presumably by improved 
sarcomere and myofibril alignment148,239. Similar studies in hiPSC-CMs 
demonstrate increased force in longer cells compared to shorter ones161. 
Investigations of the relationship between cell size and force is important, as 
cardiac myocyte size changes dramatically during cardiac development with the 
transition from immature to mature cardiac myocyte involving a significant 
increase in cell area240.   
 Force production in both adult and fetal cardiac myocytes is highly 
dependent upon the load against which the cell is contracting, which includes the 
stiffness of the immediate microenvironment241. This allows the heart to adjust 
cardiac output and this may be compromised in cases where tissue stiffness 
changes drastically, as in fibrotic diseases of the heart242. The stiffness of the 
human heart changes during development in utero; however, the elastic modulus 
of the native myocardium is still being debated and varies markedly depending 
on the method of measurement. To date, most studies report that the elastic 
modulus of the myocardium increases with age243-247. Thus, the ability to produce 
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force against varying levels of stiffness is another important marker of heart 
muscle physiologic maturity. 
 HiPSC culture media composition is another critical factor in guiding 
hiPSC-CM maturation. It is well known that the physiologic extracellular calcium 
concentration in mammalian interstitial spaces is between 1.5-2.0 mM248, 
providing a strong electrochemical gradient opposite a much smaller intracellular 
calcium concentration in heart muscle104,249. However, the calcium concentration 
in RPMI, which is the basal medium used in differentiation and growth of hiPSC-
CMs in most laboratories, is sub-physiological at 0.42 mM250. It has been shown 
by numerous groups that extracellular calcium and calcium signaling play a 
significant role in cardiac development, namely in cardiac myocyte 
hypertrophy150-151. With this information, we hypothesized that physiological 
extracellular calcium concentration is necessary for the development of force 
production in hiPSC-CMs.  
 In the present study, we investigated the developmental maturation status 
of hiPSC-CMs using single cell traction force microscopy to measure force 
production of isolated myocytes. We examined force and contractility in the 
context of several physiologically relevant environmental parameters.  First, we 
tested hiPSC-CMs contractile maturation by comparing them to neonatal rat 
ventricular myocytes (NRVMs), with a focus on cell morphology and geometry. 
Then, we measured force in response to substrates of varying stiffness. Finally, 
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we tested hiPSC-CM development during culture in varied physiologic 
extracellular calcium conditions.  
 
Methods 
Culture and Differentiation of Human iPSC-Derived Cardiac Myocytes 
Human iPSC line DF 19-9-11T, which was derived from healthy donor 
fibroblasts using a vector-free episomal induction method251, was graciously 
provided to us by the laboratory of Dr. Timothy Kamp at the University of 
Wisconsin-Madison. HiPSCs were cultured according the protocol outlined in that 
paper; briefly, cells were grown in TESR-E8 media (Stemcell, Vancouver, CA), 
on Matrigel-coated (Corning, Corning, NY) 35 mm 6 well plates, and passaged 
every 4 days via EDTA with a dilution factor of 1:12.  
 HiPSCs were differentiated using a small molecule Wnt/GSK3 inhibition 
protocol66. Briefly, hiPSCs were cultured to approximately 90% confluency, then 
treated with a GSK3 inhibitor, CHIR99021 (Stemgent, Cambridge, MA) in RPMI 
supplemented with B-27 minus insulin (Thermo Fisher, Waltham, MA) and 
Matrigel, for 24 hours. Media was replaced for 48 hours. Cells were treated with 
IWP-4 (Stemgent, Cambridge, MA) in RPMI with HEPES with B-27 minus insulin 
for 48 hours, and media was replaced every 48 hours until cells began to beat 
spontaneously, at which point they were grown in RPMI with HEPES 
supplemented with insulin-replete B-27. Media was changed every 2-3 days until 
ready for assays. Higher-calcium (physiological) media was prepared by 
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supplement RPMI + B27 growth media to 1.8 mM Ca2+ using 1M CaCl, and then 
stirred to dissolve any precipitations that form. Cells grown in physiological 
calcium media had media changed every 1-2 days, as these cells produce acidic 
media more rapidly.  
 
Isolation and Culture of Neonatal Rat Ventricular Myocytes 
All methods for handling laboratory animals were approved by the 
Institutional Animal Care and Use Committee at the University of Minnesota. One 
day-old Sprague Dawley rat pups were sacrificed via decapitation and hearts 
excised through the chest. Cardiac myocytes were isolated using sequential 
trypsin and collagenase treatments according to the protocol provided with the 
Worthington Neonatal Cardiomyocyte Isolation System (Worthington 
Biochemical, Lakewood, NJ). NRVMs were plated directly onto patterned 
polyacrylamide constructs at a density of 100,000 cells per well and cultured in 
DMEM + 4% FBS. Media was changed after 24 hours, and cells were allowed to 
continue to adhere for 48 more hours until assaying. NRVMs were treated the 
same way as hiPSC-CMs during the assay procedure.  
 
Micropatterning of Polyacrylamide Constructs 
Micropatterning stamps were created according to protocols outline by 
Wang et al152. Briefly, photomasks were designed in AutoCAD (AutoDesk, Mill 
Valley, CA) and printed by Fineline Imagine (Colorado Springs, CO).  Single cell 
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shapes were placed far enough apart to ensure contraction of one cell would not 
affect substrate deformation of neighboring cells. Stamp masters were created 
using photolithography by applying photomasks to silicon wafers coated with 
photoresist and exposing to light. Stamps were created by curing 
polydimethylsiloxane (PDMS) (Dow Corning Sylgard 184, Ellsworth Adhesives) 
on the patterned silicon master (for patterned stamp) or on an unpatterned 
silanized silicon wafer (for blank stamps). Both patterned and unpatterned 
stamps were made new each time they were used. Stamps were coated and 
stamped according to the stamp-off protocol laid out by Desai et al153. Briefly, 
blank stamps were coated with laminin (50 µg/ml in molecular biology grad 
water) and incubated for 60 minutes, then dried and inverted onto patterned 
stamps which have been UV-activated. Blank stamps were immediately peeled 
off and placed onto 15 mm coverslips which had been plasma-activated by 
running through a blue flame. Cover slips were then ready for use with gels. 
 
Polyacrylamide Gel Construction 
Polyacrylamide gels were made using ratios of Acrylamide to N,N’-
methylenebisacrylamide according to Tse et al154 and then actual gel stiffness 
was measured using uniaxial stress testing. Ahead of time, 25 mm glass 
coverslips were UV treated, then treated with 3-aminopropyltriethoxysilane for 3 
minutes, and rinsed with ethanol. Polyacrylamide was made with 1x phosphate-
buffered saline, and 0.2 µm red FluoSpheres fluorescent beads (Thermo Fisher, 
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Waltham, MA) were mixed into the unpolymerized acrylamide solution at a 
concentration of 0.005% (diluted 1:200). The solution was degassed for 15 
minutes, and to the unpolymerized solution was added 
tetramethylethylenediamine (final dilution 1:1500), and the solution was brought 
to a pH of 7 via HCl. Ammonium persulfate (final concentration 0.017% w/v) and 
N-hydroxysuccinimide ester (final concentration 0.0083 mg/ml) were added to 
solution. 15 µl of solution were quickly pipetted onto APS-treated coverslips. 
Laminin-coated coverslips were inverted onto the solution and allowed to 
polymerize at room temperature for 60 minutes. Top coverslips were removed 
from the polymerized gels, and gels were incubated in 4% BSA at 37° for 45 
minutes, then rinsed 3 times with 1x PBS.  
HiPSCs were dissociated in Accutase (Thermo Fisher, Waltham, MA) for 
20 minutes, then resuspended in warm RPMI + B27 and replated onto 
polyacrylamide gels at 100,000 cells per well. Cells adhered overnight, then 
media was changed the following morning. Cells were allowed to adhere for two 
more days, then assayed on day 3 after plating.  
 
Traction Force Microscopy and Analysis 
Experiments were performed on an Olympus X81 Inverted Microscope 
using a 40x UPLSAPO40X2, NA 0.95 objective in an environmental control 
chamber at 37° C. Images were acquired using MetaMorph software (Molecular 
Devices, Sunnyvale, CA) at a rate of 3.5 frames per second. Cells were paced at 
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0.5 Hz with a 35 mV square pulse using a MyoPacer field stimulator (IonOptix, 
Westwood, MA) in RPMI + B27 with HEPES. Cells were paced for 3-5 minutes 
before recording, and data was recorded from each dish for no more than 30 
minutes to avoid recording from dying cells. Cells were given fresh media 60 
minutes before data acquisition. 3-4 contractions were acquired from each cell.  
Images were analyzed using ImageJ code developed by Tseng et al155-156. 
Stacks of images of the cell and fluorescent beads before and during contraction 
were oriented vertically and cropped to an area of 64.4 µm wide by 128.8 µm tall 
before analysis.  
Particle image velocimetry using iterative interrogation windows of 128-64-
32 pixel width was completed between the matched bead images from the same 
cell location at different time points. The noise-filtered displacement field was 
used to calculate traction stresses with a Fourier transform traction cytometry 
(FTTC) ImageJ plugin using the Fourier transform traction cytometry method157. 
A regularization factor of 1x10-9 was applied for improved accuracy, as 
described in Stricker et al158. Stress vector magnitudes were integrated over the 
area of interest and reported as total force. Strain energy of the substrate was 
calculated for each individual hiPSC-CM as149.  
 
where T is the traction stress and u is the displacement. 
 
Statistical Methods 
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All statistical analysis was performed using Prism software (GraphPad, 
San Diego, CA). Correlation analysis was done by linear regression, and 
estimation of significant non-zero slopes was determined. Significant differences 
between groups for all other experiments was estimated by one-way ANOVA 
with a Tukey’s post hoc test. Significant differences in Figure 5 were estimated 
with a Student’s T test. Spline plots were created using MATLAB (Mathworks, 
Natick, MA). 
 
Results  
HiPSC-CMs Align and Contract Along a Single Axis 
Human iPSC-CMs were transferred to polyacrylamide (PA) gels that had 
been micropatterned with laminin rectangles with an area of 2000 µm2 and an 
aspect ratio of 7:1, which has been reported as an ideal aspect ratio for NRVM 
force production148. This allowed individual hiPSC-CMs to adhere to the 
substrate and occupy an area of up to 2000 µm2. Here, hiPSC-CMs formed a 
rectangular shape aligned along the direction of the long axis of the patterned 
area (Figure 2.1A).  Most hiPSC-CMs formed geometries with an area smaller 
than 2000 µm2 and an aspect ratio slightly smaller than 7:1 (Figure 2.1F).  
 Patterned single hiPSC-CMs were paced via field stimulator at 0.5 Hz and 
35 mV. Paced myocytes contracted along their long axes, creating visible 
deformations in the fluorescent bead-containing substrate. Particle image 
velocimetry analysis showed greatest substrate displacement towards the ends 
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of the hiPSC-CMs, as well as in areas surrounding the ends of the cells (Figure 
2.1B). Traction force analysis showed that the largest traction stress was 
developed in the substrate at these same locations (Figure 2.1C). Averaged 
contractions showed a force development curve resembling that of adult cardiac 
myocytes (Figure 2.1D, E)252. hiPSC-CM calculated force measurements were 
on the order of 10-8 N, which is in line with measurements previously reported by 
others161. 
 
Heterogeneous Cell Geometry Affects Contractility 
In general, current practice differentiation protocols result in the 
development of a heterogeneous population of contractile cells, as evidenced by 
varied electrophysiological parameters253, calcium handling254 and gene 
expression profiles255. We thus sought to examine the potential effects of 
geometric heterogeneity on physiologic force production. Micropatterned PAA 
constructs were designed as a rectangle with a 7:1 aspect ratio and a 2000 µm2 
surface area. HiPSC-CMs that have been cultured on the constructs are able to 
occupy an area of up to 2000 µm2, in their preferred aspect ratio, which ranged 
from 4:1 to as long as 10:1, with a mean of 6.6:1 (Figure 2.1F).  
Based on this outcome, we examined the effects of cell geometry on 
contractility. We first measured total force production of d90 hiPSC-CMs on a 5 
kPa substrate. There was a significant positive correlation between cell size and 
total force produced (Figure 2.2A, R2 = 0.21, P = 0.02). However, we found no 
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correlation between long axis (length), short axis (width), or aspect ratio and 
force. Based on these findings, for the remainder of this paper we report total 
force, as well as force per unit area, which we refer to here as normalized force. 
 
Development of hiPSC-CMs under Prolonged Culture Conditions 
It is widely accepted that hiPSC-CMs phenotypically resemble immature 
cardiac myocytes and, depending on the studied characteristics, resemble 
embryonic cardiac myocytes256, fetal cardiac myocytes69,234, or neonatal cardiac 
myocytes119. Furthermore, with increased culture time, a more mature phenotype 
can be obtained. Accordingly, we examined TFM-based force production of 
hiPSC-CMs after 14 days, 30 days, or 90 days in culture and compared to 
NRVMs. 
 At d14, hiPSC-CMs produce small but detectable amounts of force, 
whereas d30 cells produce significantly more total force and normalized force 
(one-way ANOVA p < 0.0001) (Figure 2.3A-C). At d90, single hiPSC-CMs 
produce more total force than at d30. However, as they are also larger, 
normalized force is not significantly different (Figure 2.3D). However, d90 cells 
produce significantly more total force (p < 0.0001) and normalized force (p < 
0.0001) than d14 cells. D90 cells were significantly larger than d14 cells (P = 
0.01). NRVMs showed similar cell size and total force produced compared to d90 
hiPSC-CMs; however, they had significantly higher normalized force (P < 0.05).  
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Effects of Substrate Mechanics on Contractility 
Cardiac myocyte work adapts significantly during development20.  
Furthermore, cardiac myocytes produce different amounts of traction in response 
to altered mechanical environments160,257. To investigate whether this holds true 
for hiPSC-CMs, we cultured hiPSC-CMs for 30 days under normal growth 
conditions, then transferred isolated hiPSC-CMs to PAA gels with a defined 
modulus of 3.1, 9.8, or 13.5 kPa. hiPSC-CMs produced decreased total force 
(one-way ANOVA, P < 0.0001) (Figure 2.4A) and normalized force (one-way 
ANOVA P < 0.0001) (Figure 2.4C) as a function of increased substrate stiffness. 
HiPSC-CMs on 3.1 kPa modulus substrate produced significantly more force 
than on 9.8 or 13.5 kPa (Figure 2.4A, C). Cell area was not significantly different 
between conditions, indicating the range of substrate stiffness tested was not 
enough to induce changes in cell spreading, and that cell spreading was not the 
cause of differential force production (Figure 2.4B). At a substrate modulus 
higher than 13.5 kPa, bead displacement was very small, resulting in a poor 
signal-to-noise ratio (data not shown). We also calculated strain energy 
generated by each cell during a full contraction and found a decrease in strain 
energy with increasing stiffness. This correlated to decreased force production, 
with cells on a substrate with a modulus of 3.1 kPa substrates generating 
significantly more energy than those on substrates with a modulus of 9.8 or 13.5 
kPa substrates (one-way ANOVA P < 0.0001).  
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Effects of Extracellular Calcium on hiPSC-CM Development 
Typical hiPSC-CM growth medium contains sub-physiological levels of 
calcium (~0.42 mM), whereas physiologic extracellular calcium concentrations 
are much higher, ranging from 1.3 mM258 to 2.0 mM254,259-260. To examine the 
effects of media calcium concentrations on hiPSC-CMs, we cultured hiPSC-CMs 
in growth media that had been supplemented with CaCl up to 1.8 mM Ca2+, 
beginning on the day that they began spontaneously contracting (d7), and 
continuously until they were tested (d30). hiPSC-CMs in media with physiologic 
calcium levels produced greater total force than cells grown in standard growth 
medium, when assayed in standard growth medium (P = 0.0073) (Figure 2.5A). 
Additionally, these hiPSC-CMs were significantly larger (P = 0.0004) (Figure 
2.5B). However, specific force was not significantly different between the two 
groups (p = 0.75) (Figure 2.5C). 
 
Discussion 
Human induced pluripotent stem cell-derived cardiac myocytes are an 
attractive model system for experimental therapeutic discovery and as a potential 
cell/tissue source for regenerative therapy in diseased hearts. However, a 
significant obstacle to realizing this potential is the physiologic immaturity of 
hiPSC-CMs relative to adult cardiac myocytes. In this study, we utilized traction 
force microscopy to rigorously investigate absolute force production in isolated 
single hiPSC-CMs. Relative to other methods of assaying cardiac myocyte 
  84 
contractility, single cell traction force microscopy eliminates potential confounding 
effects of neighboring cells, including myocytes and fibroblasts. Here, our study 
has several main findings, including establishing an inverse relationship between 
force and substrate stiffness. This is potentially significant for ongoing and future 
studies attempting to translate hiPSC-CMs for regenerative therapies for the 
diseased myocardium in vivo. 
Additional new findings include guiding hiPSC-CM area and aspect ratio to 
adopt a rectangular shape with a single contractile axis force vector to 
demonstrate that force production correlates with overall cell area but not length, 
width, or aspect ratio. This led us to normalize all force measurements to cell 
area in order to obtain a more accurate representation of cellular contractile 
performance, termed here as normalized force. While aspect ratio did not 
correlate to total force, aspect ratios were distributed normally around with a 
mean between 6:1 - 7:1, which is very close to the aspect ratio that other groups 
have determined for hiPSC-CMs and NRVMs to produce maximal force148,161. 
Data further shows that hiPSC-CMs progress along a timeline similar to 
the natural embryonic development of cardiac myocytes, wherein normalized 
force increases as myocytes mature69,238. Results show hiPSC-CM normalized 
force increases as a function of time in culture, which is in line with results from 
other research groups160. Analysis of single hiPSC-CMs, as compared to 
neonatal rat ventricular myocytes using identical assay conditions, show that 
hiPSC-CMs produce comparable total force as NRVMs. While instructive, these 
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results also show that it is not yet possible to achieve physiologic maturation in 
terms of force output approaching that of adult cardiac myocytes. 
The stiffness of the human heart increases during development243-244, 
prompting us to investigate the ability of hiPSC-CMs to produce force against 
substrates of varying elastic moduli. We implemented here three moduli that are 
in line with the range that a cardiac myocyte encounters as the heart develops 
from an embryonic state to adult244. Data show that both total force and 
normalized force decrease as substrate modulus increases from 3.1 kPa to 9.8 
kPa - 13.5 kPa, in agreement with a recent report161. These findings are in 
contrast to another earlier study; however, it is difficult to directly compare 
findings due to the higher force variability in that work160. This discrepancy may 
be due to different methods of creating polyacrylamide constructs, or potentially 
to different methods of measuring the stiffness of the hydrogel. 
Another new finding of this study is the elucidation of strain energy applied 
by hiPSC-CMs to the surrounding environment. Strain energy characterizes the 
work done by the cell on the underlying substrate, which is important to 
contractile cells, including hiPSC-CMs. It has been shown that fibroblasts 
generate similar amounts of strain energy on substrates of different stiffness149. 
However, as shown here, hiPSC-CMs generate less strain energy in the 
deformation of stiffer substrates. We posit that in hiPSC-CMs, due to their 
immaturity, they are better able to produce force against a substrate that more 
closely mimics the stiffness of an embryonic heart than that of an adult or fibrotic 
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heart. We speculate that an understanding of strain energy in hiPSC-CMs can 
help decipher the basis of the difficulties encountered by groups attempting to 
transplant immature hiPSC-CMs in diseased adult myocardium63.   
Finally, we discovered that ionic content of media for long-term hiPSC-CM 
culture has important outcomes in terms of cellular maturation and force output. 
The effects of extracellular calcium on the developing heart has been explored 
recently150-151, with evidence that cells with sub-physiological calcium influx are 
smaller than those with normal calcium gradients and signaling. With hiPSC-CMs 
in vitro, a unique opportunity is present to track force development while 
modifying extracellular calcium levels directly. Data show increases in hiPSC-
CMs normalized force during culture with physiologic calcium levels (1.8 mM) 
compared to widely used standard RPMI calcium levels (0.4 mM). This is 
important because calcium signaling is crucial for cardiac myocytes in terms of 
excitation-contraction coupling104,261 as well as signaling through calcium binding 
proteins, such as calmodulin262 and calcineurin263. Collectively, this is evidence 
that differentiation and development protocols that attempt to recapitulate 
embryonic development should take into consideration the concentrations of all 
electrolytes, including calcium.  
Taken together, these new data show that the functionality of hiPSC-CMs, 
as determined by their ability to produce force against a substrate via single cell 
TFM, closely resembles that of an immature cardiac myocyte. Specifically, in 
terms of the impact of geometry on hiPSC-CM contractility, total normalized force 
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production by single myocyte TFM is similar to that of neonatal rat cardiac 
myocytes. As hiPSC-CMs perform more optimally working on less stiff 
substrates, we report hiPSC-CMs function is comparable to neonatal cardiac 
myocytes. Ultimately, quantitative analysis of hiPSC-CM contractile performance 
as done here via traction force microscopy will be critical toward optimization of 
culture content and cell environment, including matrices, to advance the  
maturation state of hiPSC-CM toward human adult myocardium. 
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Figure 2.1. HiPSC-CMs and measurement of force by TFM. A, Representative 
cell, 30 days post-differentiation on a 9.8 kPa substrate. B, Heat map showing 
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magnitudes of deformation strain of the substrate under the representative cell. 
C, Heat map showing magnitudes of stress of the representative cell calculated 
from strain of the substrate. D, total force of a single cell over time with respect to 
baseline at the point t = 0 seconds, over four contractions paced at 0.5 Hz, fitted 
with a smoothed spline curve. E, total force of a single cell over time, average of 
four contractions, fitted with a smoothed spline curve. F, histograms showing 
distribution of cell geometries. 
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Figure 2.2. Effects of single cell hiPSC-CM morphology on force production. A, 
peak force versus cell area, R2 = 0.21, P<0.03   B, peak force versus long axis 
(axis of contraction). C, peak force versus short axis (perpendicular to axis of 
contraction). D, peak force versus aspect ratio (long axis/short axis).  
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Figure 2.3. Effects of length of hiPSC differentiation on force production. A, 
representative hiPSC-CMs from day 14, day 30, and day 90 post-differentiation, 
and representative NRVM. B, total force versus length of differentiation (mean = 
0.012 ± 0.001 µN, n = 17; 0.083 ± 0.013 µN, n = 15; 0.103 ± 0.011 µN, n = 24; 
0.113 ± 0.016 µN, n = 12). C, cell area versus length of differentiation (mean = 
605.7 ± 47.1 µm2, 702.3 ± 63.2 µm2, 898.2 ± 64.4 µm2, 741.9 ± 61.4 µm2). D, 
normalized force versus length of differentiation (mean = 2.12 ± 0.23 mN/mm2 x 
10-5, 13.0 ± 2.14 mN/mm2 x 10-5, 11.4 ± 1.4 mN/mm2 x 10-5, 15.3 ± 1.5 mN/mm2 
x 10-5). 
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Figure 2.4. Effects of substrate stiffness on hiPSC-CM force production. A, total 
force versus substrate elastic modulus (mean = 0.236 ± 0.02 µN, n = 21; 0.083 ± 
0.01 µN, n = 15; 0.075 ± 0.01 µN, n = 22). B, area versus substrate elastic 
modulus (mean = 754.9 ± 31.5 µm2, 702.3 ± 63.2 µm2, 851.6 ± 43.7 µm2). C, 
normalized force versus substrate elastic modulus (mean = 32.4 ± 3.5 mN/mm2 x 
10-5, 13.0 ± 2.1 mN/mm2 x 10-5, 9.1 ± 1.0 mN/mm2 x 10-5). D, strain energy 
versus substrate elastic modulus (mean = 29.7 ± 4.3 fJ, 5.5 ± 1.7 fJ, 3.1 ± 0.6 fJ). 
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Figure 2.5. Effects of calcium concentration in growth media on hiPSC-CM force 
production. A, total force versus calcium concentration (mean = 0.083 ± 0.013 
µN, n = 15; 0.147 ± 0.02 µN, n = 14). B, cell area versus calcium concentration 
(mean = 702.3 ± 63.2 µm2, 1130.3 ± 86.2 µm2). C, normalized force versus 
calcium concentration (mean = 13.0 ± 2.14 mN/mm2 x 10-5, 14.0 ± 2.0 mN/mm2 
x 10-5). 
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Chapter 3 
Inducible Expression of Mature Cardiac Markers Improves the Maturation 
Status of hiPSC-CMs 
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Abstract 
 Cardiovascular medicine and regenerative biology have benefited greatly 
from recent advances in the ability to differentiate cardiac myocytes from human 
induced pluripotent stem cells (hiPSC-CMs). hiPSC-CMs have the benefit of 
being human cells, being virtually unlimited in supply, and being readily 
propagated in a short period of time. They have the potential to be a valuable 
model for studying cardiovascular physiology. However, hiPSC-CMs have been 
shown to exist in an immature state, more closely resembling embryonic cardiac 
myocytes than adult cardiac myocytes, limiting the amount of information that 
can be applied from hiPSC-CM studies to adult cardiac physiology. Here, we 
used genome editing to create hiPSC-CMs that can be induced to express one of 
two genes closely associated with cardiac maturation- SERCA2a or cardiac 
troponin I (cTnI). We found that overexpression of SERCA2a leads to enhanced 
physiologic function in terms of calcium handling and contractility kinetics, 
especially in response to isoproterenol. Additionally, SERCA2a expression leads 
to upregulation of other markers of maturation, such as cTnI. Expression of cTnI 
in iPSC-CMs leads to global changes in the gene expression profile as measured 
by RNAseq, including upregulation of important cardiac and developmental 
genes, and downregulation of genes associated with non-ventricular phenotypes. 
Overall, expression of proteins associated with maturity results in enhanced 
maturation of hiPSC-CMs. 
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Introduction 
The fields of cardiovascular physiology, regenerative biology, and clinical 
medicine have benefited significantly from recent advances in the ability to 
differentiate cardiac myocytes from pluripotent cells. Notably, the ability to 
reprogram a human somatic cell to an induced pluripotent stem cell state 
(hiPSC)41, and then to differentiate these cells into cardiac myocytes (hiPSC-
CMs)66. In this setting, the investigator has exclusive control over the 
environment of the cell in its earliest stages of differentiation. This approach 
provides an almost unlimited source of human cardiac cells for experimentation 
and for potential use as a therapeutic agent.  
One promising use of hiPSC-CMs has been as a model for myocardial 
disease and dysfunction. To date, research groups have used hiPSC-CMs to 
study electrophysiological parameters, including studies examining the effects of 
mutations in sodium channels75,77. In addition, investigations of calcium handling 
defects have been conducted by examining the effects of mutations in calcium 
handling proteins82. Futhermore, mitochondrial dysfunction has been studied by 
examining the effects of mutations in mitochondrial proteins83. These examples 
emphasize a significant strength of hiPSC-CMs, which is, they express human 
isoforms of proteins implicated in disease states. Furthermore, mutations in these 
proteins can be precisely isolated, and either introduced or potentially corrected 
by genome editing, given the pliable developmental state of the pluripotent 
cells224-225.  
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However, it has been demonstrated by several groups that hiPSC-CMs, 
differentiated according to current protocols, exist in an immature developmental 
state, and that they more closely resemble neonatal myocytes than adult cardiac 
myocytes. For example, action potentials and pharmacology show increased 
susceptibility to arrhythmia93, ultrastructure shows less-developed sarcoplasmic 
reticulum and myofibrillar patterns264, isoforms of critical sarcomeric proteins are 
predominantly immature174, and calcium currents show immature contributions of 
extracellular versus intracellular transporters113. Thus, attempts to study effects 
of dysfunctional proteins in hiPSC-CMs lead to conclusions that must necessarily 
be interpreted in the context of an immature myocyte.  
To address this limitation, we investigated here the roles of two genes 
associated with a mature developmental state on the function of hiPSC-CMs. 
First, we addressed the role of induced overexpression of the sarco/endoplasmic 
reticulum calcium ATPase SERCA2a, the calcium pump of the sarcoplasmic 
reticulum (SR) membrane. SERCA2a is the major protein responsible for 
removal of calcium from the cytoplasm during diastole and reuptake into the SR 
to be stored for the next calcium release. It is known that the amplitude and 
kinetics of intracellular calcium transients change during cardiac development, 
with increasing SERCA2a expression in more mature cardiac myocytes188. In 
addition, it is known that SERCA2a expression declines in failing myocardium187.  
Second, we investigated troponin I, the key molecular switch of the 
troponin complex responsible for regulating myosin binding to actin for 
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contraction and relaxation of the sarcomere. Specifically, since hiPSC-CMs 
express almost exclusively the immature isoform of troponin I, slow skeletal 
troponin I (ssTnI), we studied the effects of expression of the adult isoform, 
cardiac troponin I (cTnI), which has important effects on sarcomere mechanics 
and kinetics140,165. Collectively, by employing genome editing platforms with 
inducible functionality, we tested here whether targeted expression of key adult 
genes can advance maturation in hiPSC-CMs. 
 
Methods 
hiPSC Culture and Differentiation 
The human induced pluripotent stem cell line used in this paper was the 
DF 19-9-11 line, graciously gifted to us by the Timothy Kamp lab, which is 
derived from foreskin dermal fibroblasts and is transgene- and vector-free251. 
hiPSCs were cultured as previously described; cells were grown in TeSR-E8 
media (Stemcell, Vancouver, CA) in plastic dishes coated with Matrigel (Corning, 
Corning, NY) and passaged by 0.5 mM EDTA in PBS when they reached 90% 
confluency, and replated with Rho kinase inhibitor 10 µM Y-27632 (Selleckchem, 
Houston, TX).  
hiPSCs were differentiated at 90-95% confluency in 35 mm dishes 
according to the small molecule Matrigel sandwich method published 
previously66. At day 0, cells were treated with Matrigel dissolved in RPMI + B27 
supplement minus insulin (Thermo Fisher, Waltham, MA) with 10 µM CHIR99021 
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(Stemgent, Lexington, MA), which is a GSK3 inhibitor. On day 2, media was 
changed without addition of small molecules. On day 3, cells were treated with 
10 µM IWP-4 (Stemgent, Lexington, MA), an inhibitor of Wnt signaling, in RPMI + 
B27 supplement minus insulin. On day 5 and every 2 days after that, media was 
changed until cells started to beat vigorously, approximately day 7-10, at which 
point media was switched to RPMI plus B27, insulin-replete.  
For all assays that involved dissociation and replating of cells, cells were 
dissociated with Accutase (Thermo Fisher, Waltham, MA) for 30 minutes at room 
temperature, followed by mechanical dissociation with a P1000 pipet and 
centrifugation for 3 minutes at 800 rpm.  
 
Genome Editing 
Genome editing was carried out by a pair of TALENs specific to the 
AAVS1 locus on chromosome 19, with a template plasmid containing homology 
arms specific to the targeted site and a tetracycline-inducible promotor-effector 
system265. The genes of interest (SERCA2a or cTnI) human cDNAs were 
designed with restriction sites to fit into the template plasmid and constructed by 
Integrated DNA Technologies (Coralville, IA), and then cloned into digested 
template plasmids.  
All three plasmids (forward TALEN, reverse TALEN, and template) were 
transfected into undifferentiated hiPSCs at a concentration of 15 µg per 400 µl 
cuvette volume by electroporation using the Bio-Rad Gene Pulser Xcell (Bio-Rad, 
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Hercules, CA), using an exponential waveform with parameters of 250 V, 400 µF, 
and infinite resistance. hiPSCs were replated onto 25 mm wells coated with 
Matrigel and allowed to recover for 3-4 days. Puromycin selection was done 
starting with 0.2 µg/ml and increasing to 1 µg/ml over the course of 5-7 days. 
Individual surviving colonies were dissociated and replated, and continued to be 
passaged as in the above methods. Undifferentiated hiPSCs collected for RNA 
samples were treated with doxycycline on days 1 and 2 after passaging. In order 
to express the gene of interest in hiPSC-CMs, differentiated cells were treated 
with doxycycline from day 42 to day 60, so that experiments were carried out on 
d60 cells after 2 weeks of gene induction. 
 
RNA Isolation and Real-Time PCR 
RNA was collected from undifferentiated hiPSCs before doxycycline and 
after 24 or 48 hours of treatment with doxycycline. hiPSCs were isolated with 
EDTA as in the passaging protocol mentioned above, then spun at 800 RPM for 
3 minutes and treated with the RNEasy Plus kit (Qiagen, Hilden, Germany) and 
quantified by NanoDrop spectrophotometry (NanoDrop, Wilmington, DE). In 
parallel studies, RNA was collected from differentiated hiPSC-CMs by 
dissociation with Accutase (Thermo Fisher, Waltham, MA) for 25 minutes at room 
temperature, then spun at 800 RPM for 3 minutes and treated with the RNEasy 
Plus kit and quantified by NanoDrop spectrophotometry. 
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Next, cDNA libraries were created using the Superscript Vilo kit (Thermo 
Fisher, Waltham, MA) and quantitative real-time PCR was performed using the 
Bio-Rad SYBR Green qPCR Master Mix Bio-Rad, Hercules, CA) on an 
Eppendorf Mastercycler machine (Eppendorf, Hamburg, Germany). Primers were 
designed using the Integrated DNA Technology PrimerQuest tool (IDT, Coralville, 
IA) and synthesized by IDT. Analysis of expression and fold change was carried 
out using the ddCt method266, with GAPDH used as a housekeeping gene.  
 
Western Blot and Protein Quantification 
Protein was extracted by mechanical dissociation in RIPA buffer and 
quantified by Pierce BCA protein assay (Thermo Fisher, Waltham, MA). All 
samples were denatured by boiling and β-mercaptoethanol. 20 µg of protein in 
Laemmli buffer was loaded into each lane, and samples were run on 12% SDS-
PAGE gels at 120 V until the dye front reached the end of the gel. Protein was 
transferred to PVDF membranes. Membranes were stained for SERCA2a (2A7-
A1, Abcam, Cambridge, UK), ssTnI (MAB1691, Millipore, Billerica, MA), pan-TnI 
(1E7, Novus, Littleton, CO), and cardiac actin (5C5, Santa Cruz Biotechnology, 
Dallas, TX). Membranes were imaged on the LI-COR Odyssey (LI-COR, Lincoln, 
NE). 
 
Calcium Imaging 
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Differentiated hiPSC-CMs grown in a monolayer were loaded with Fura-2 
AM (Thermo Fisher, Waltham, MA) at 1 µM in RPMI + B27 supplement with 1.8 
mM calcium for 10 minutes at room temperature, then allowed to de-esterify for 
10 minutes at 37°C. Isoproterenol was used at a concentration of 10 nM, as 
previously described267. Experiments were carried out at 37°C using the IonOptix 
myocyte calcium and contractility system (IonOptix, Westwood, MA). Ratiometric 
calcium transients were curve-fitted and analyzed using the IonOptix software. 
We measured spontaneous transient rate, time to peak, and time to 75% 
baseline in d14 unedited cells (soon after spontaneous beating begins in culture), 
d60 unedited cells treated with doxycycline, and d60 SERCA2a overexpressing 
cells treated with doxycycline for 2 weeks. These measurements were made at 
baseline and in response to 100 nM isoproterenol, a β-adrenergic agonist. 
  
Impedance Measurement and Contractility 
Here, 35 day old differentiated hiPSC-CMs were dissociated and replated 
at a density of 80,000 cells per well into a 96-well Nanion Sensor Plate (Nanion, 
Munchen, Germany) that had been coated with Matrigel, and allowed to adhere 
18 hours. Media was changed after 18 hours and then every 2 days after that. 
Cells generally began beating again 7 days after replating, at which point 
baseline impedance measurements were recorded. hiPSC-CMs were treated 
with doxycycline for 2 weeks after that, so that cells were 2 months old in culture 
at the time of post-induction measurements. Impedance was measured on the 
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Nanion CardioExcyte 96. Measurements were taken at 5 minute intervals over 
the course of 1 hour in an environmentally-controlled chamber at 37°C and 5% 
CO2. Isoproterenol was used at a concentration of 10 nM. hiPSC-CMs formed 
syncytia after several days in culture and contracted simultaneously. hiPSC-CMs 
were not electrically stimulated, as attempts to do so interfered with the ability of 
this platform to collect accurate data. We measured at baseline and in response 
to isoproterenol, before and after 2 weeks of treatment with doxycycline. We 
measured time from 10% to 90% peak and time from 90% to 10% return to 
baseline 
Data was exported to a txt file and transients were analyzed using 
Clampfit™ software (Molecular Devices, Sunnyvale, CA) to normalize to baseline 
and to fit a sum of exponents curve to raw impedance data. 
 
RNA Sequencing 
RNA sequencing was performed by the Bioinformatics group at the 
Morgridge Institute for Research, at the University of Wisconsin Madison. hiPSC-
CMs were cultured and dissociated as above and RNA was extracted from 
dissociated cells using the RNEasy Plus kit (Qiagen, Hilden, Germany) and 
quantified by NanoDrop spectrophotometry (NanoDrop, Wilmington, DE). 
Samples were processed for quality control on an Agilent Bioanalyzer (Agilent, 
Santa Clara, CA) and a Qubit Fluorometer (Thermo Fisher, Waltham, MA). 
Libraries were created using Ligation Mediated RNA sequencing (LM-seq)268 and 
  104 
sequenced on a HiSeq 2500 (Illumina, San Diego, CA). Transcript counts 
reported as transcripts per kilobase million (TPM) were compared between 
groups for each gene and Bonferroni statistical tests were performed using CLC 
Sequence Viewer (Qiagen, Hilden, Germany). 
 
Statistical Analysis 
All statistical analysis other than that done on RNA sequencing data was 
performed using Prism (GraphPad, San Diego, CA). All groups of data were 
analyzed by ANOVA. Paired data was analyzed by Student’s t test. RNA 
sequencing data was analyzed as above. 
 
Results 
Genome Editing Results in Long-term Expression of Inducible Genes 
Undifferentiated hiPSC-CMs were edited, as outlined in the methods, 
using a pair of TALENs directed against the AAVS1 locus on chromosome 19 
(Figure 3.1a). The gene of interest, either SERCA2a or cTnI, was cloned into a 
template plasmid containing sequences homologous to the AAVS1 site, allowing 
the gene of interest and tetracycline-inducible promoter system to be introduced 
to the site via homology-directed repair. Cells that had undergone HDR were 
selected for by puromycin-resistant selection. 
In order to establish the kinetics of the tetracycline-inducible promoter 
system, expression of SERCA2a RNA transcripts was examined in 
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undifferentiated hiPSCs before doxycycline treatment and after 24 and 48 hours 
of doxycycline treatment. Here, qPCR showed increased expression after 24 and 
48 hours of treatment, indicating rapid responsivity of the system (Figure 3.1b). 
In hiPSC-CMs that had been edited to contain an exogenous SERCA2a gene, 
Western blot analysis showed a 5.6-fold increase in SERCA2a expression 
compared to edited cells without doxycycline at the same time point (P = 0.05) 
(Figure 3.2a). In hiPSC-CMs that had been edited to express the adult cTnI 
gene, Western blot analysis showed increased of expression of cTnI after 
induction with tetracycline for 2 weeks; quantification shows a 4.3-fold increase in 
the ratio of cTnI: ssTnI (P = 0.16) (Figure 3.2b).  
 
Induced expression of SERCA2a Enhances Calcium Handling and 
Adrenergic Responsivity 
To examine the role of induced SERCA2a on the physiology of hiPSC-
CMs, we used the ratiometric calcium indicator Fura-2 AM to visualize and 
quantify spontaneous calcium transients (Figure 3.3). At baseline, spontaneous 
transient rate was not significantly different between among unedited and edited 
cells with or without doxycycline. However, while d14 and d60 unedited cells do 
not display a chronotropic response to isoproterenol, the d60 SERCA cells had a 
significant (P < 0.05) response, indicating increased adrenergic responsivity.  
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The d60 unedited cells did not have a response to isoproterenol in time to 
peak; however, d60 SERCA cells show marked decrease in time to peak after 
isoproterenol treatment compared to baseline (P < 0.05). 
 
Induced Expression of SERCA2a Leads to Improved Contractility Kinetics 
and Adrenergic Responsivity in hiPSC-CMs 
Induction of SERCA2a expression in hiPSC-CMs would be expected to 
display altered cell contractility. We utilized here an impedance measurement 
system to track contractility of a syncytium of spontaneously beating d60 hiPSC-
CMs (Figure 3.4). Prior to doxycycline, there were no significant differences 
between unedited and edited hiPSC-CMs, wherein each exhibited similar 
decreased time to peak and decreased time to baseline in response to 
isoproterenol. However, after treatment with doxycycline, SERCA2a hiPSC-CMs 
showed shortened time to peak at baseline compared to doxycycline-treated 
unedited cells (Figure 3.4a). 
 
Induced Expression of SERCA2a Results in Increased Expression of 
Mature Cardiac Genes 
By Western blot, markers of improved maturity or physiologic function 
were examined in hiPSC-CMs. In the SERCA edited iPSC-CMs, we tested 
whether increased expression of SERCA2a could induce developmental 
maturation of the hiPSC-CMs, including proteins not directly associated with 
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intracellular Ca2+ handling. We found that upregulation of SERCA2a in hiPSC-
CMs for two weeks with doxycycline treatment significantly increased the cTnI: 
ssTnI ratio compared to hiPSC-CMs of the same age without doxycycline (P < 
0.05) (Figure 3.5). 
 
Induced Expression of cTnI Alters hiPSC-CM Gene Expression Profiles 
TnI is a physiologically crucial protein that shows a robust switch from 
ssTnI to cTnI in the development of immature to mature cardiac myocytes165. 
There is some evidence that in some tissues, some TnI isoforms may localize to 
the nucleus and facilitate gene transcription269. Thus, we speculated that turning 
on production of cTnI may have far-reaching effects on the gene expression 
profile of the cell.  To study this, we performed RNAseq on cTnI overexpressing 
cells that had been induced with doxycycline, and compared results with 
unedited cells that had been treated with doxycycline. In order to account for 
potential effects of heterogeneity of differentiated cell populations (cardiac 
myocyte versus other cell types) as well as proliferation or death of cardiac 
myocytes, we normalized transcripts per kilobase million (TPM) values of each 
gene to TnC TPM values for that group.  
After filtering for genes with a Bonferroni test statistic p < 0.05 and 
normalizing to cardiac troponin C (cTnC), we found 586 genes upregulated and 
41 genes downregulated in cTnI hiPSC-CMs compared to unedited cells at the 
same time point after treatment with doxycycline (Figure 3.6a, b). Importantly, we 
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found that the mRNA ratio of cTnI: ssTnI was higher in cTnI overexpressing cells 
compared to unedited cell, or edited cells without doxycycline, indicating 
appropriate induction of cTnI (Figure 3.6b).  
Using DAVID pathway analysis software, we analyzed pathways and gene 
clusters that were upregulated or downregulated in cTnI hiPSC-CMs. 
Downregulated clusters included genes associated with early development and 
BMP signaling, as well as genes associated with non-cardiac or early-cardiac 
calcium signaling and muscle contraction (Figure 3.7a). Upregulated pathways 
included many clusters associated with cardiac muscle contraction, calcium 
signaling, and late development. Additionally, genes associated with cell 
migration, morphogenesis, cell-cell contact, and regulation of ROS were highly 
expressed (Figure 3.7b).  
The list of upregulated genes included several genes crucial to the 
development and maturation of cardiac myocytes, and ventricular cardiac 
myocytes in particular, including MYH6, MYOM3, TTN, and MYL9, which are 
cardiac-specific sarcomeric genes. Calcium handling genes such as RYR2, 
CACNB2, and CALML4, which are important for cardiac calcium handling were 
upregulated; also, developmental genes including GATA4 and HAND2 were 
expressed. Downregulated genes included Grem2270, coding for the protein 
Gremlin, which is important for atrial myocyte development; HCN4, which is 
associated with pacemaker cells; NKX2.5, which is an early cardiac development 
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gene; and several skeletal muscle-specific genes, including ACTA1 and MB 
(Figure 3.7).  
 
Discussion 
In this paper, we examined the effects of induced overexpression of two 
key proteins involved in cardiac myocyte maturation, SERCA2a and cardiac TnI. 
We found that induced expression of SERCA2a led to altered physiologic 
function of hiPSC-CMs, including increased responsiveness of calcium transients 
to adrenergic signaling, and faster contractile kinetics. Furthermore, induced 
expression of cTnI resulted in widespread changes in the gene expression profile 
of hiPSC-CMs as seen by RNAseq, including upregulation of genes and 
pathways associated with ventricular myocyte development and regulation. 
SERCA2a is critical for removal of calcium from the cytoplasm during 
diastole104, allowing the cell to relax while loading the SR with calcium for release 
during the next contraction. It communicates with other calcium handling proteins 
and sarcomeric proteins, and its function is modulated by adrenergic signaling 
pathways187. Expression of SERCA2a increases as cardiac myocytes mature into 
adult myocytes; decreased SERCA2a is also associated with myocardial failure, 
and restoration of SERCA2a can improve myocardial performance188. 
Furthermore, hiPSC-CMs have altered calcium handling properties compared to 
adult myocytes188, making SERCA2a an attractive target for overexpression.  
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cTnI is an important marker of the switch from immaturity to maturity, as 
immature cardiac myocytes express nearly 100% ssTnI, and mature cardiac 
myocytes express nearly 100% cTnI, and this does not change in heart failure238. 
cTnI has profound effects on the contractile kinetics of the myocyte, namely in its 
ability to respond to adrenergic signaling and allow the sarcomere to experience 
increased chronotropy while maintaining sarcomere length shortening140. 
The choice to introduce genes that are associated with cell maturity, but 
that have important roles in the physiologic function of the myocyte, allows us to 
probe the ways that these proteins have effects in both areas. Both are crucial for 
researchers using hiPSC-CMs to study human myocardial disease and function. 
Additionally, our data showed important feedback and communication between 
the two genes of choice- induced expression of SERCA results in increased 
expression of cTnI, as well as changes in contractility kinetics. Also, RNAseq 
showed that induced expression of cTnI resulted in increased expression of 
genes associated with cardiac calcium handling, including CALML4 and RYR2. 
Thus, both systems, sarcomeric and calcium handling, seem to be both 
necessary and sufficient for induction of maturation in hiPSC-CMs.  
The maturation status of the hiPSC-CM affects proteins that are involved 
in calcium handling, contractility, and other physiologic function, as well as 
proteins that are less directly involved, such as proteins involved in development, 
metabolism, hypertrophy, transcription, and cell motility and survival. Here, our 
RNAseq data demonstrated that overexpression of cTnI can lead to global 
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changes in gene expression in line with increased maturity. This includes a shift 
towards ventricular cardiac myocytes, as seen by the increased expression of 
cardiac genes such as MYOM3, MYL9, CALML4, RYR2, and TPM2. 
Furthermore, there was a shift away from atrial cardiac myocytes, which 
predominate at earlier developmental time points, shown by the downregulation 
of Grem2, and from pacemaker cells, shown by the downregulation of HCN4. 
Interestingly, the data showed evidence of a shift away from skeletal muscle 
lineages, seen by the downregulation of CASQ1, ACTA1, and ENO3, suggesting 
that either these genes are important in the early development of cardiac 
myocytes, or that the current differentiation protocol may not be specific to 
cardiac myocytes. 
Our data demonstrates that overexpression of mature cardiac proteins 
addresses both the immediate- and long-term physiologic functionality of hiPSC-
CMs. With only 2 weeks of overexpression of SERCA2a, we saw changes in the 
calcium handling and contractile properties of hiPSC-CMs. SERCA-
overexpressing hiPSC-CMs calcium transients, while unchanged at baseline, had 
significantly increased responsivity to isoproterenol, including shortened time to 
peak and increased chronotropy. On the other hand, SERCA-overexpressing 
cells at baseline had improved contractile kinetics in terms of time to peak at 
baseline, as well as in response to isoproterenol, compared to unedited cells. 
Our results suggest that overexpression of a critical regulator of physiologic 
performance, especially one involved in the transport of calcium, which is an 
  112 
important signaling ion, may have additional downstream effects on other 
calcium handling, sarcomeric, and adrenergic signaling proteins, either through 
direct activation or inactivation, or through altered transcriptional regulation of 
those genes. 
These results emphasize the importance of studying the function and 
effects of wild-type cardiac proteins in hiPSC-CMs, especially those involved with 
a mature cardiac myocyte phenotype. A complete understanding of their effects 
on maturation and physiology may lead to a better understanding of the basic 
physiology of hiPSC-CMs, and may allow us to more rigorously study disease-
causing mutations in cardiac genes, as well as pathology-inducing environmental 
conditions. Ultimately, this will lead to a better and more efficient model of heart 
disease and failure that may lead to improved therapies and clinical benefit. 
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Figure 3.1. A, genome editing schematic. Forward and reverse TALENs make a 
DSB at the AAVS1 safe harbor site, and template DNA containing the inducible 
gene of interest is inserted by HDR. B, quantification of SERCA2a mRNA in 
undifferentiated hiPSCs in response to doxycycline (mean 1.0-fold, 5.57 ± 5.84-
fold, 26.49 ± 15.02-fold, p < 0.05). C, quantification of cTnI mRNA in 
undifferentiated hiPSCs in response to doxycycline (mean 1.0-fold, 71221 ± 
68248-fold, 77543 ± 68208-fold). 
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Figure 3.2. A, Western blot and quantification of SERCA2a in SERCA2a-
overexpressing cells in response to doxycycline, normalized to sarcomeric actin 
(mean 0.06 ± 0.09, n = 4, 0.34 ± 0.6, n = 4). B, Western blot and quantification of 
cTnI in cTnI-overexpressing cells in response to doxycycline, expressed as a 
ratio of cTnI: ssTnI (mean 0.03 ± 0.02, n = 4, 0.13 ± 0.10, n = 4).  
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Figure 3.3. Calcium transients in hiPSC-CMs, unedited at day 14 and day 60 
post-differentiation, and SERCA-overexpressing hiPSC-CMs at day 60 post-
differentiation, at baseline and in response to isoproterenol. A, calcium 
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transients per minute (mean 61.22 ± 11.89, 61.5 ± 8.08, 53.67 ± 13.03, 62.91 ± 
7.44, 54.23 ± 11.60, 111.5 ± 11.2, p < 0.05). B, magnitude of transient peak as a 
percent of baseline ratio (mean 6.26 ± 1.30, 8.15 ± 1.22, 3.20 ± 1.09, 4.61 ± 1.31, 
3.47 ± 1.64, 5.11 ± 1.81). C, time to peak of transient from baseline (mean 0.14 ± 
0.32, 0.15 ± 0.39, 0.09 ± 0.02, 0.10± 0.03, 0.13 ± 0.04, 0.05 ± 0.008, p < 0.05). 
D, time from transient peak to 75% baseline (mean 0.40 ± 0.08, 0.47 ± 0.10, 0.23 
± 0.05, 0.24 ± 0.07, 0.37 ± 0.10, 0.26 ± 0.04). E, representative traces in 
unedited cells before and after isoproterenol. F, representative traces in SERCA-
overexpressing cells before and after isoproterenol.  
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Figure 3.4. Impedance measurements in unedited and SERCA-overexpressing 
hiPSC-CMs, before and after treatment with doxycycline, with response to 
isoproterenol. A, time from 10% to 90% peak (mean in Unedited 170.2 ± 35.2, 
124.7 ± 69.7, 170.5 ± 80.9, 118.3 ± 47.3, mean in SERCA 180.7 ± 124.7, 141.0 ± 
159.0, 140.0 ± 110.2, 121.1 ± 52.7). B, time from 90% to 10% baseline (mean in 
Unedited 263.5 ± 69.5, 221.4 ± 55.7, 280.8 ± 84.8, 258.8 ± 37.6, mean in SERCA 
231.2 ± 90.1, 197.9 ± 65.8, 209.1 ± 86.7, 191.9 ± 48.7). C, representative traces 
of impedance measurements of unedited and SERCA-overexpressing hiPSC-
CMs after treatment with doxycycline, no isoproterenol.  
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Figure 3.5. A, Western blot for cTnI and ssTnI in SERCA-edited hiPSC-CMs with 
and without doxycycline. B, quantification of Western blot (mean 0.04 ± 0.05, 
0.16 ± 0.03, p < 0.05). 
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Figure 3.6. A, Venn diagram showing genes with significantly different (P < 0.05) 
read counts in cTnI-overexpressing hiPSC-CMs versus unedited hiPSC-CMs 
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after treatment with doxycycline. 627 genes in the left-most region were used for 
the analysis. B, Of the 627 genes, 41 were downregulated and 586 were 
upregulated.  
 
  121 
 
  122 
 
Figure 3.7. A, major pathways involved in downregulated genes. B, major 
pathways involved in upregulated genes. C, important genes that were 
upregulated or downregulated. 
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Chapter 4 
General Discussion 
 
Conclusions 
The experiments in this thesis have focused heavily on the physiological 
function of human induced pluripotent stem cell-derived cardiac myocytes. 
Broadly, this thesis focuses on two major topics- first, the force-producing 
properties of hiPSC-CMs in their native state, that is, without marked genetic, 
pharmacologic, electrical, or mechanical modifications, utilizing the state of the 
cells as they are grown and differentiated according to the current commonly-
used protocols66. Second, we focused on changes to physiological function of 
hiPSC-CMs that occur in response to a major, but conceptually simple, 
modification to the cell, which is the overexpression of a wild-type, 
developmentally important protein that has an immediate role in either the 
calcium handling or contractile properties of the myocyte.  
The first major project utilized traction force microscopy (TFM), a 
technique that has been in use for several years now to examine contractile 
properties of various cell types including fibroblasts145, keratocytes146, 
osteoblasts147, and neonatal rat ventricular myocytes148. TFM allows us to 
optically determine the amount of force a cell produces against a substrate of 
known elastic modulus. We have implemented TFM here to determine the peak 
force of single isolated hiPSC-CMs, paced at a physiologic frequency of 1 Hz, 
  124 
against physiologic substrate stiffness of between 2.5 to 9.3 kPa244, normalized 
to cell area, based on the finding that peak force positively correlates with cell 
size.  
In this part of the project, the emphasis was on determining the contractile 
function of hiPSC-CMs that had been differentiated according to the most 
commonly used protocol by current labs66, a protocol that is fairly straightforward 
and simple, and that efficiently produces high numbers of cardiac myocytes. This 
was important to us, because we had felt that while some researchers had 
characterized aspects of their function79,112, a fundamental understanding of 
force development, which is the central physiologic function underlying the very 
existence of myocytes, was lacking. Force output in hiPSC-CMs should be 
established before extrapolating results of more complex experiments, such as 
disease modeling by introduction of genetic mutations, to human physiology. 
Furthermore, we wished for other researchers to be able to use the results of our 
experiments to guide their own work.  
These experiments provided us with evidence of physiology that was 
mostly in line with what we would expect, with some important caveats. First, that 
force production correlates with cell size- this is unsurprising, given the structure-
function of a cardiac myocyte. However, unlike adult cardiac myocytes, we did 
not find force to correlate with cell width. We found that force production 
increased as hiPSC-CMs mature in culture. This relationship was evident to a 
  125 
point where they plateau no matter whether they are continued to be kept in 
culture, and force normalized to cell area never reaches that of a NRVMs.  
We found that hiPSC-CMs produce less force on stiffer substrates, which 
is in line with what some groups have found with hiPSC-CMs161, but different 
than others160. A critical finding of this project was that the extracellular calcium 
concentration is crucial for cardiac myocyte development, with hiPSC-CMs that 
are grown in physiologic levels of extracellular calcium producing more force than 
those grown in RPMI + B27, which is the accepted growth media for hiPSC-
CMs66.  
The second major project involved overexpression of critical cardiac proteins in 
hiPSC-CMs to modulate physiology and maturation. We chose two proteins that 
play important roles in the physiology and development of cardiac myocytes, and 
that would be likely to have significant effects on hiPSC-CM function. SERCA2a, 
responsible for removal of calcium from the cytoplasm during diastole, and for 
loading the SR with calcium104, has effects on calcium handling, cell contractility, 
adrenergic responsivity, and cardiac myocyte development188. Next, we targeted 
cTnI, which is the adult isoform of troponin I and part of the thin filament. It is 
exclusively expressed in adult cardiac myocytes, and is partially responsible for 
the sarcomere’s ability to accelerate contractility kinetics in response to 
adrenergic signaling140.  
The driving idea behind this part of the project was that we could use 
these proteins to modulate both the immediate physiology of the cell, as well as 
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the developmental status of the cell. With both genetically-engineered cell lines, 
those that had been edited to contain an inducible exogenous SERCA2a gene, 
and those that had been edited to contain an inducible exogenous cTnI gene, we 
found both cases to be true. Using a fluorescent calcium reporter, we found 
evidence that overexpression of SERCA led to enhanced calcium transient 
activity in the face of adrenergic stimulation (isoproterenol). Furthermore, these 
hiPSC-CMs had increased spontaneous transient rate and faster time to peak 
after isoproterenol challenge. Using an impedance measuring system, we were 
able to track contractility of syncytia of cells at baseline and in response to 
isoproterenol, and found that although both edited and unedited cells had faster 
contraction in response to isoproterenol, overexpression of SERCA led to 
shortened contraction times at baseline, as well as further response to 
isoproterenol.  
Western blot of SERCA overexpressing cells showed increased 
expression of key markers associated with a switch to maturity, including cTnI, 
indicating cell-wide changes in gene expression involving genes not directly 
involved in calcium handling. Similarly, RNAseq analysis of cTnI overexpressing 
cells showed global changes in gene expression in edited cells treated with 
doxycycline compared to unedited cells treated with doxycycline for a month. 
Changes included upregulation of genes important to the maturation and 
development of cardiac myocytes, including cardiac myosin heavy chain, and 
downregulation of genes involved in earlier stages of cardiac myocyte 
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development, such as Gremlin, which is important for atrial myocyte 
differentiation but not ventricular270.  
This series of experiments, progressing from more descriptive analysis of 
baseline cellular function to advanced genomic engineering, depict hiPSC-CMs 
as an innovative and powerful research tool. Here, with intact physiologic and 
genomic function that in many ways resemble mature cardiac myocytes, we find 
evidence that hiPSC-CMs are able to produce force and contract with vigor, 
which is the ultimate purpose of a cardiac myocyte. Additionally, these hiPSC-
CMs are able to appropriately respond to adrenergic stimulation, as seen by 
increased chronotropy and accelerated kinetics.  
Alongside the similarities, these experiments reveal some significant 
insights that we believe should be taken into consideration by researchers in 
future experiments. For example, force production never quite reaches the same 
level as an NRVMs. Thus, any experiments involving mutations that decrease 
contractility should take this into account. In terms of gene and protein 
expression, we here confirm previous findings by us and other groups112 that 
immature isoforms of certain proteins, such as troponin I, are predominantly 
expressed versus mature isoforms. Finally, the understanding that the standard 
differentiation and growth media used for hiPSC-CMs, RPMI + B27 supplement, 
has an extremely low calcium concentration, and that this significantly impacts 
the development of hiPSC-CMs compared to media with physiologic calcium 
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levels. This finding should be an important technical consideration for future 
experiments. 
The most important takeaway from these experiments, though, is the 
power of hiPSC-CMs as a genetically malleable system for human cardiac 
muscle research. The immaturity of hiPSC-CMs, and the fact that, only several 
weeks previously, they were derived from pluripotent cells, is a boon to the field 
in that their genomes are amenable to editing by genome editing technologies, 
such as TALENs, as shown here. Furthermore, because we have access to and 
control over the developmental environment of the cells the entire way from 
pluripotency to terminally differentiated cardiac myocyte, there are seemingly 
endless possible ways of manipulating hiPSC-CMs in order to study factors that 
are important to cardiac development.  
Genome editing provides a precise and permanent way of introducing 
genetic modifications to the cell. Genome editing can be used to introduce 
mutations, or correct mutations in an already-mutated cell line. It can be used to 
knock out a gene that may be developmentally important, but that may result in 
embryonic lethality, limiting its ability to be studied in vivo. It can also be used to 
overexpress a gene of interest that may have significant impacts on myocyte 
function. Here, we have used genome editing to permanently introduce an 
inducible gene expression system. Our data demonstrate that genome editing 
can be used effectively and efficiently to implement hiPSC-CMs as a tool for 
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studying physiologically relevant genes and their role in human cardiac muscle 
function and development.   
 
Clinical Implications 
hiPSC-CMs have several potential roles in clinical medicine. First, hiPSC-
CMs can be used as a model of disease. Second, hiPSC-CMs can be used for 
drug discovery. Third, hiPSC-CMs can be used as a transplantable therapy. As a 
model system, as mentioned earlier, there have been attempts to utilize hiPSC-
CMs for drug testing and drug discovery. For example, they have been proposed 
as an alternative to other cell types overexpressing the hERG channel. There 
have been some encouraging results, including validation of several previously-
validated drugs91. hiPSC-CMs are an attractive tool for drug discovery because, 
unlike other cell types, they express not only hERG, but other ion channels that 
may be potentially arrhythmogenic90. Furthermore, hiPSC-CMs have action 
potentials, which are a sum of currents through several ion channels, rather than 
a single channel, and which can be measured using electrical recording.  
However, hiPSC-CMs can have considerable variability of action potential 
waveform, presumably from differential contribution of ion channels253 and from 
reduced currents compared to adult cardiac myocytes, such as the inwardly 
rectifying IK1 current, and spontaneous activity due to unopposed funny current 
If271. To improve hiPSC-CMs as a model of drug discovery, it may be beneficial to 
utilize genome engineering to overexpress channels that are poorly expressed, 
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such as IK1, or to use siRNAs to reduce If. Also, because intracellular calcium 
concentrations75 have effects on membrane currents, such as by influencing the 
NCX, or by signaling through calmodulin, overexpression of SERCA2a may have 
important effects on the action potential, and may result in an action potential that 
more closely resembles that of an adult cardiac myocyte. 
As a model of cardiac disease, hiPSC-CMs have shown the potential to be 
used to study mechanisms of disease, as well as potential therapeutic 
treatments. Here, several examples have already been mentioned of researchers 
that have used hiPSC-CMs derived from patients with various cardiovascular 
diseases, such as long QT75, Timothy syndrome81, and catecholaminergic 
polymorphic ventricular tachycardia82. While most of these studies have so far 
served to corroborate findings found in mouse models of the disease or in human 
patients, some of these studies have discovered additional findings that may be 
relevant to disease mechanisms. Thus, the CPVT study was able to show that 
dantrolene, shown to have beneficial effects in mouse model of CPVT272, also 
has positive effects on the phenotype of the derived hiPSC-CMs.  
Our genome editing and gene induction data highlights the potential of 
using hiPSC-CMs as a model of disease. While it can be convenient to derive 
pluripotent cells from patients that are known to have a disease-causing 
mutation, it is not possible to do so for every disease. It is also quite difficult to 
separate the effects of the mutation from the effects of potentially confounding 
factors, such as SNPs present in other genes, although these biases may be 
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mitigated by comparing cells from patients with a disease against cells from their 
siblings. However, because hiPSC-CMs can be modified according to the desires 
of the researcher, mutations that are desirable to study, but may not be found in 
patients, could be introduced precisely into the genome of the pluripotent stem 
cell. Furthermore, entire genes could be transiently upregulated or 
downregulated at any point in the development of the cell, such as at the 
beginning of differentiation, in order to model congenital diseases and 
abnormalities, or farther along in the differentiation process, in order to model 
diseases in more mature cardiac cells.  
However, as has been repeatedly stated above, our data shows that 
hiPSC-CMs are still quite immature regardless of how long the cells have been in 
culture, and this affects the quality of data the comes out of physiologic studies. 
Studies on the effects of mutated genes in the context of their effects on 
contractility and calcium handling give us only hypothetical scenarios of how 
those mutations might affect an adult cell. To counteract this, it may be useful to 
upregulate a gene associated with maturity, such as SERCA2a or cTnI, and then 
examine the effects of the mutation or disease-causing gene. In this way, results 
from those experiments will be more relevant to adult cardiac disease, especially 
in the study of congestive heart failure, which is one of the most critical health 
problems facing the world today2. 
Finally, hiPSC-CMs may prove to be an important and powerful 
therapeutic agent in heart failure, ischemic heart disease, and cardiac infarction. 
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It has been proposed that hiPSC-CMs injected into a diseased myocardium may 
provide mechanical support, electrical support, metabolic support, or paracrine 
signaling support to the native cardiomyocytes30. The desired maturity of the 
transplanted cells may depend on the desired outcome. For example, an 
immature hiPSC-CM may be more likely to promote cardiac regeneration in the 
native tissue due to secretion of developmentally important growth factors or 
secretion of immature extracellular matrix proteins. On the other hand, a more 
mature cardiac myocyte may be more likely to provide structural support through 
increased force development, or increased electrophysiological support through 
mature calcium handling or action potentials. Furthermore, our modified cells 
show a greatly enhanced response to isoproterenol. This, along with mature 
calcium handling and ionic currents, may make mature transplanted cells less 
prone to arrhythmia, and may make them less prone to causing re-entrant circuit 
arrhythmias in the native heart64.  
 
Future Directions 
This project, while a substantial effort, barely scratches the surface of 
possibilities of what we can learn from hiPSC-CMs. Utilizing traction force 
microscopy, we have shown that it is possible to precisely measure contractility 
by measuring the peak force production of a single, isolated hiPSC-CM. We have 
begun to investigate factors that affect force production, such as length of 
differentiation, substrate stiffness, cell geometry, and extracellular calcium 
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concentration. This is a powerful tool, and has the potential to be used to explore 
additional force-modulating factors. These could be divided into elements that 
are present in the embryo, factors that are present in the adult heart, external 
factors such as drugs and chemical modulators, and individual genes, along with 
their isoforms and splice variants. 
As hiPSC-CMs most closely resemble embryonic or immature cardiac 
myocytes, factors that affect an embryonic cardiac myocyte’s ability to produce 
force may be examined using traction force microscopy. For example, it has 
been shown that the stiffness of the extracellular environment that the cell 
senses affects things such as development of action potentials273, and likely has 
an impact on the amount of developed force produced by a myocyte. Factors that 
affect hypertrophy, such as insulin and IGF274, as well as other maternal and fetal 
hormones, may affect contractility, as may growth factors that affect cardiac 
patterning and growth55. Electrical stimulation has been shown to have effects on 
hiPSC-CM development275 as well. All of the above treatments are easily 
implementable in hiPSC-CM culture and may be valuable sources of improved 
maturity in terms of contractility and force. 
In the adult heart, many of the same factors that affect the embryonic 
heart are also present, except that in this case, alterations in these environmental 
factors may cause improved function, as in an exercised heart, or decreased 
function, as in a failing heart. Extracellular stiffness “felt” by the myocytes has 
already been noted to have a key role on myocyte function, as failing hearts are 
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significantly stiffer than non-failing hearts244. Electrical abnormalities, as 
arrhythmias, are strongly linked to heart failure, although it is currently hard to 
say whether arrhythmias have as much effect on contractility as cardiac myocyte 
derangement has on arrhythmogenesis276; hiPSC-CMs may serve to elucidate 
this. Hormones, such as insulin277 or cortisol278, have been shown to have crucial 
effects on cardiac function, and may be easily introduced into hiPSC-CM culture 
to probe their effects. 
As mentioned above, a particularly promising medical application of 
hiPSC-CMs is in drug discovery and testing. There are numerous drugs either 
available clinically or tested experimentally that have been shown to modulate 
cardiac myocyte contractility. Drugs such as digoxin, which increases intracellular 
calcium279; levosimendan, which increases calcium sensitivity280; and omecamtiv 
mecarbil, which activates myosin281, are all considered either full or partial 
positive inotropes, and might be expected to increase force production. These 
applications highlight hiPSC-CMs as a potential template for drug discovery. 
Conversely, negative inotropes, such as milrinone, which is a PDE3 inhibitor283, 
would be expected to have negative effects on force production. 
We have shown that genetic engineering and overexpression of 
physiologically important genes such as SERCA2a and cTnI have significant 
effects on contractility and gene expression. An important next step is to 
determine whether cells that overexpress either of these genes also have altered 
force development. Genome engineering and gene transfection can be used to 
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over- or under-express a wide variety of genes. These might fall into the category 
of sarcomeric proteins that have direct effects on force development, such as 
myosin heavy chain and myosin light chain isoforms283-284 or myosin binding 
protein C285, or proteins that modify the function of sarcomeric proteins, including 
the adrenergic signaling pathway, including adrenergic receptors and protein 
kinase A286. Other potentially force-modifying genes include those involved in 
hypertrophy, such as Akt194, or genes involved in ion handling, such as the 
sodium potassium ATPase or dihydropyridine receptor287.  
Additionally, TFM can and should be modified to keep up with current 
technological developments in the field. For example, the assay used in its 
current form in this thesis suffers from the classical imaging trade-off between 
resolution and image capture speed- because the PIV algorithm relies on high-
resolution images of small 0.2 µm fluorescent beads with a high signal-to-noise 
ratio, images were captured at a rate of 3-4 frames per second. Because the time 
to peak and time to relaxation of an isolated contracting myocyte are on the order 
of hundreds of milliseconds267, the absolute peak contraction may be missed by 
the assay. Utilization of a faster microscope would allow peak to be captured 
precisely, and may allow contractility kinetics to be explored by the assay as well, 
assuming images are captured at constant intervals. High resolution microscopy 
is improving to the point where this may be possible in the near future288. Other 
improvements may come in the form of improved microcontact printing or 
hydrogel formation that may reduce the amount of labor involved in each assay, 
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or may improve survivability of hiPSC-CMs during the process of dissociation 
and replating onto hydrogels.  
In the second part of the thesis, we have demonstrated the enormous 
potential of hiPSCs and hiPSC-CMs to be modified and manipulated in order to 
modulate maturity and manage physiologic function. By introducing two genes, 
cTnI and SERCA2a, using an inducible promoter, we have shown proof-of-
principle of real-time modulation of physiology. Knowing this, one can envision 
and almost unlimited number of experiments using genome editing to modulate 
function and maturity in hiPSC-CMs. Furthermore, having a permanently-inserted 
genetic system would allow us to examine the effects of gene induction alongside 
other techniques that may induce maturity, such as electrical stimulation or 
cyclical stretch, with the hope that they would work in synchrony to produce 
adult-like cardiac myocytes. 
In this thesis, we used an inducible promoter, which has the benefit of 
allowing us to turn on in a time-dependent manner and when we believe it will 
have the most impact. For our purposes, this was at 42 days after the start of 
differentiation, a time point where the cells have reached some level of maturity 
compared to earlier time points, as based on traction force microscopy, but 
where the cells are still far from behaving like mature cardiac myocytes. 
However, it could be particularly useful to induce maturity genes at various time 
points, such as early in development, later in culture, or even before the 
differentiation process began, while the cells were undifferentiated pluripotent 
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stem cells. Furthermore, removing induction by removing doxycycline leading to 
a decrease in expression of the exogenous gene, would inform whether the 
effects are transient, lasting only as long as the protein is present, or whether it 
leads to permanent changes in the cell, indicating a more terminally mature cell 
type.  
Tissue-specific promoters or developmental stage-specific promoters 
would be useful to study the effects of a gene without having to continuously 
expose the cell to doxycycline, which may potentially have unexpected effects on 
the cell, and which would be difficult to utilize in cells that were transplanted into 
a patient. Cardiac specific promoters, though, could be driven by a promoter 
such as the β-MHC promoter, which is present in both immature and mature 
cardiac myocytes185. The promoter could be used to drive additional genes 
associated with maturity, such as myosin light chain 2v172, or it could be used to 
drive expression of siRNAs that inhibit translation of genes associated with 
immaturity, such as ANP, skeletal actin, or GLUT178. Alternatively, immature 
transcription factors and promoters could be used to induce expression of a more 
mature gene; for example, the transcription factor Nkx2.5, which is highly 
expressed in developing embryonic cardiac myocytes289, could be used to drive 
expression of cTnI or α-MHC. One could envision a series of genes, each slightly 
more mature than the previous, and driven by a slightly less-mature promoter, 
leading to a chain reaction of gene expression that closely recapitulates cardiac 
development in the embryo. This might allow for testing that important 
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checkpoints along the path of differentiation from pluripotent cell to adult 
cardiomyocyte are met. 
Physiologic function should be rigorously assessed after each 
modification, utilizing TFM or similar assays, in order to ensure that results from 
each experiment are directly comparable to each other. We have outlined several 
assays, including calcium handling, traction force microscopy, and impedance 
measurements for contractility, that are reliable and rigorous, and that test three 
essential functions of a myocyte: calcium, force, and kinetics. Other assays, 
including patch clamp and extracellular field potential, should be considered. 
Additionally, assays that measure the force of a syncytium of cells, rather than a 
single cell, should be used, as cells may behave differently in a syncytium than 
they do as isolated cells235.  
While we have used RNA sequencing, which is a powerful method of 
examining the complete set of genes expressed by the cell, to probe the 
developmental state and maturity of our cells, at the very least, important 
markers of maturity should be looked for by Western blot. Immunofluorescence 
or electron microscopy could also be used to study the structure of the cells. 
Immunofluorescence can provide indications of cell size and hypertrophy, as well 
as myofibril number and organization290. Electron microscopy can provide 
information about the ultrastructure of sarcoplasmic reticulum and T-tubules291, 
mitochondria292, and sarcomeres, including sarcomere size and shear angle293. 
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Finally, mutations and genetic causes of disease should be studied and 
can be highly informative regarding human disease, once it is understood what 
role the wild-type protein plays in the physiology of an hiPSC-CM. For example, 
once we understand how the composition of the troponin complex in hiPSC-CMs 
affects the cell’s contractility and adrenergic response, then it is appropriate to 
perform experiments using mutations in troponin T or troponin C. It may be that it 
is necessary to overexpress cTnI to a sufficient level before introducing 
mutations into other troponins, in order to be able to extrapolate results of those 
experiments to diseases in the adult or even childhood heart. It may turn out that 
modification of a wild-type protein, including overexpression of a mature protein, 
has no effect on the physiology of the cell. In this case, it would be reasonable to 
draw conclusions from experiments using mutations or modifications of that 
protein that could be relevant to human disease or modeling.  
Taken together, this thesis demonstrates the vast significance of stem 
cells and stem cell-derived cardiac myocytes in the future of cardiovascular 
medicine. We have demonstrated that, while stem cell-derived cardiac myocytes 
represent an immature state, they have enormous potential for both scientific 
discovery and for therapeutic use in cardiovascular disease. We have shown that 
physiologically-relevant assays are available to measure important functional 
parameters, including force development, which are sensitive to physiologic 
stimuli including substrate stiffness and extracellular calcium concentration. A 
major advantage of hiPSC-CMs over mouse models is that they express human 
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proteins, which can be examined in the context of a human cell. A major 
advantage of hiPSC-CMs over primary human cardiac myocytes, though, is the 
incredible genetic malleability of the cells. Here we have shown precise genetic 
control over the cells as they develop from pluripotent stem cells to a terminally 
differentiated cell type. We have been able to examine the role of wild-type, 
physiologically important proteins on both the short-term function of the cell, as 
well as the long-term gene expression profiles. Human stem cell-derived cardiac 
myocytes are therefore a powerful tool for the future of cardiovascular health. 
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